



Waage, J., Standl, M., Curtin, J. A., Jessen, L. E., Thorsen, J., Tian, C., Schoettler, N., the 23 and Me Research Team (2018). Genome-wide association and HLA fine-mapping studies identify risk loci and genetic pathways underlying allergic rhinitis. *Nature Genetics*, 50(8), 1072-1080. <https://doi.org/10.1038/s41588-018-0157-1>

Peer reviewed version

Link to published version (if available):  
[10.1038/s41588-018-0157-1](https://doi.org/10.1038/s41588-018-0157-1)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Springer Nature at <https://www.nature.com/articles/s41588-018-0157-1>. Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

# Genome-wide association and HLA fine-mapping studies identify risk loci and genetic pathways underlying allergic rhinitis

Johannes Waage<sup>1†</sup>, Marie Standl<sup>2†</sup>, John A Curtin<sup>3</sup>, Leon E Jessen<sup>1</sup>, Jonathan Thorsen<sup>1</sup>, Chao Tian<sup>4</sup>, Nathan Schoettler<sup>5</sup>, The 23andMe\_Research\_Team<sup>6</sup>, AAGC\_collaborators<sup>6</sup>, Carlos Flores<sup>7,8</sup>, Abdel Abdellaoui<sup>9,10</sup>, Tarunveer S Ahluwalia<sup>1</sup>, Alexessander C Alves<sup>1†</sup>, Andre F S Amaral<sup>12</sup>, Josep M Antó<sup>13</sup>, Andreas Arnold<sup>14</sup>, Amalia Barreto-Luis<sup>7</sup>, Hansjörg Baurecht<sup>15</sup>, Catharina EM van Beijsterveldt<sup>9</sup>, Eugene R Bleeker<sup>16</sup>, Sílvia Bonàs-Guarch<sup>17</sup>, Dorret I Boomsma<sup>9,18</sup>, Susanne Brix<sup>19</sup>, Supinda Bunyavanich<sup>20</sup>, Esteban Burchard<sup>21,22</sup>, Zhanghua Chen<sup>23</sup>, Ivan Curjurić<sup>24,25</sup>, Adnan Custovic<sup>26</sup>, Herman T den Dekker<sup>27,28</sup>, Shyamali C Dharmage<sup>29</sup>, Julia Dmitrieva<sup>30</sup>, Liesbeth Duijts<sup>27,28,31</sup>, Markus J Ege<sup>32</sup>, W James Gauderman<sup>23</sup>, Michel Georges<sup>30</sup>, Christian Gieger<sup>33,34</sup>, Frank Gilliland<sup>23</sup>, Raquel Graneli<sup>35</sup>, Hongsheng Gui<sup>36</sup>, Torben Hansen<sup>37</sup>, Joachim Heinrich<sup>2,38</sup>, John Henderson<sup>35</sup>, Natalia Hernandez-Pacheco<sup>7,39</sup>, Patrick Holt<sup>40</sup>, Medea Imboden<sup>24,25</sup>, Vincent WV Jaddoe<sup>28,41</sup>, Marjo-Riitta Jarvelin<sup>11,42,43,44</sup>, Deborah L Jarvis<sup>12</sup>, Kamilla K Jensen<sup>45</sup>, Ingileif Jónsdóttir<sup>46,47</sup>, Michael Kabesch<sup>48</sup>, Jaakko Kaprio<sup>49,50,51</sup>, Ashish Kumar<sup>24,52,53</sup>, Young-Ae Lee<sup>54,55</sup>, Albert M Levin<sup>56</sup>, Xingnan Li<sup>57</sup>, Fabian Lorenzo-Diaz<sup>39</sup>, Erik Melén<sup>52,58</sup>, Josep M Mercader<sup>17,59,60</sup>, Deborah A Meyers<sup>16</sup>, Rachel Myers<sup>5</sup>, Dan L Nicolae<sup>5</sup>, Ellen A Nohr<sup>61</sup>, Teemu Palviainen<sup>50</sup>, Lavinia Paternoster<sup>35</sup>, Craig E Pennell<sup>62</sup>, Göran Pershagen<sup>52,63</sup>, Maria Pino-Yanes<sup>7,8,39</sup>, Nicole M Probst-Hensch<sup>24,25</sup>, Franz Rüschemann<sup>64</sup>, Angela Simpson<sup>3</sup>, Kari Stefansson<sup>46,47</sup>, Jordi Sunyer<sup>13</sup>, Gardar Sveinbjörnsson<sup>46</sup>, Elisabeth Thiering<sup>2,64</sup>, Philip J Thompson<sup>65</sup>, Maties Torrent<sup>66</sup>, David Torrents<sup>17,67</sup>, Joyce Y Tung<sup>4</sup>, Carol A Wang<sup>68</sup>, Stephan Weidinger<sup>15</sup>, Scott Weiss<sup>69</sup>, Gonneke Willemsen<sup>9</sup>, L Keoki Williams<sup>36,70</sup>, Carole Ober<sup>5</sup>, David A Hinds<sup>4</sup>, Manuel A. Ferreira<sup>71</sup>, Hans Bisgaard<sup>1</sup>, David P Strachan<sup>72</sup>, Klaus Bønnelykke<sup>1</sup>

<sup>1</sup>COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. <sup>2</sup>Institute of Epidemiology I, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany. <sup>3</sup>Division of Infection, Immunity and Respiratory Medicine, The University of Manchester, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK. <sup>4</sup>23andMe, Inc., Mountain View, California, USA. <sup>5</sup>Department of Human Genetics, University of Chicago, Chicago IL, USA. <sup>6</sup>Listed in the Supplementary Information. <sup>7</sup>Research Unit, Hospital Universitario N.S. de Candelaria, Universidad de La Laguna, Tenerife, Spain. <sup>8</sup>CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. <sup>9</sup>Department of Biological Psychology, Netherlands Twin Register, VU University, Amsterdam, The Netherlands. <sup>10</sup>Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. <sup>11</sup>Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment & Health, School of Public Health, Imperial College, London, UK. <sup>12</sup>Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College London, London, UK. <sup>13</sup>ISGlobal-Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra (UPF), CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain. <sup>14</sup>Clinic and Polyclinic of Dermatology, University Medicine Greifswald, Greifswald, Germany. <sup>15</sup>Department of Dermatology, Venereology and Allergology, University-Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. <sup>16</sup>Divisions of Pharmacogenomics and Genetics, Genomics and Precision Medicine, Department of Medicine, University of Arizona College of Medicine, Tucson, AZ, USA. <sup>17</sup>Barcelona Supercomputing Center (BSC). Joint BSC-CRG-IRB Research Program in Computational Biology, Barcelona, Spain. <sup>18</sup>EMGO Institute for Health and Care Research, Amsterdam, The Netherlands. <sup>19</sup>Department of Biotechnology and Biomedicine, Technical University of Denmark, Kgs. Lyngby, Denmark. <sup>20</sup>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. <sup>21</sup>Department of Medicine, University of California San Francisco, San Francisco, California, USA. <sup>22</sup>Department of Bioengineering & Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA. <sup>23</sup>Dept of Preventive Medicine, University of Southern California, Keck School of Medicine. <sup>24</sup>University of Basel, Basel, Switzerland. <sup>25</sup>Swiss Tropical and Public Health Institute, Basel, Switzerland. <sup>26</sup>Department of Paediatrics, Imperial College, London, UK. <sup>27</sup>The Generation R Study Group, Department of Pediatrics, division of Respiratory Medicine, Rotterdam, the Netherlands. <sup>28</sup>Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands. <sup>29</sup>Allergy and Lung Health Unit, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia. <sup>30</sup>Laboratory of Animal Genomics, Unit of Medical Genomics, GIGA Institute, University of Liège, Belgium. <sup>31</sup>Department of Pediatrics, division of Neonatology, Rotterdam, the Netherlands. <sup>32</sup>LMU Munich, Dr von Hauner Children's Hospital, Munich and German Center for Lung Research (DZL), Munich, Germany. <sup>33</sup>Research Unit of Molecular Epidemiology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany. <sup>34</sup>Institute of Epidemiology II, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany. <sup>35</sup>MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, UK. <sup>36</sup>Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, MI, USA. <sup>37</sup>Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Department of

Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. <sup>38</sup>Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University of Munich Medical Center, Ludwig-Maximilians-Universität München, Munich, Germany. <sup>39</sup>Genomics and Health Group, Department of Biochemistry, Microbiology, Cell Biology and Genetics, Universidad de La Laguna, La Laguna, Tenerife, Spain. <sup>40</sup>Telethon Kids Institute (TKI), Perth, Australia. <sup>41</sup>The Generation R Study Group, Department of Pediatrics, Rotterdam, the Netherlands. <sup>42</sup>Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland. <sup>43</sup>Biocenter Oulu, University of Oulu, Oulu, Finland. <sup>44</sup>Unit of Primary Care, Oulu University Hospital, Oulu, Finland. <sup>45</sup>Department of Bio and Health Informatics, Technical University of Denmark, Kgs. Lyngby, Denmark. <sup>46</sup>deCODE genetics / Amgen Inc, Reykjavik, Iceland. <sup>47</sup>Faculty of Medicine, University of Iceland, Reykjavik, Iceland. <sup>48</sup>Department of Pediatric Pneumology and Allergy, University Children's Hospital Regensburg (KUNO), Regensburg, Germany. <sup>49</sup>Department of Public Health, University of Helsinki, Helsinki, Finland. <sup>50</sup>Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland. <sup>51</sup>National Institute for Health and Welfare, Helsinki, Finland. <sup>52</sup>Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. <sup>53</sup>Department of Public Health Epidemiology, Unit of Chronic Disease Epidemiology, Swiss Tropical and Public Health Institute, Basel, Switzerland. <sup>54</sup>Max-Delbrück-Center (MDC) for Molecular Medicine, Berlin, Germany. <sup>55</sup>Clinic for Pediatric Allergy, Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin, Germany. <sup>56</sup>Department of Public Health Sciences, Henry Ford Health System, Detroit, MI, USA. <sup>57</sup>Divisions of Genetics, Genomics and Precision Medicine, Department of Medicine, University of Arizona College of Medicine, Tucson, AZ, USA. <sup>58</sup>Sachs' Children's Hospital, Stockholm, Sweden. <sup>59</sup>Programs in Metabolism and Medical & Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. <sup>60</sup>Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. <sup>61</sup>Institute of Clinical Research, University of Southern Denmark, Department of Obstetrics & Gynecology, Odense University Hospital, Odense, Denmark. <sup>62</sup>School of Medicine and Public Health, Faculty of Medicine and Health, The University of Newcastle, Callaghan, Australia. <sup>63</sup>Centre for Occupational and Environmental Medicine, Stockholm County Council, Stockholm. <sup>64</sup>Ludwig-Maximilians-University of Munich, Dr. von Hauner Children's Hospital, Division of Metabolic Diseases and Nutritional Medicine, Munich, Germany. <sup>65</sup>Institute for Respiratory Health, Harry Perkins Institute of Medical Research, University of Western Australia, Nedlands, Australia. <sup>66</sup>Ib-Salut, Area de Salut de Menorca, Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma de Mallorca, Spain. <sup>67</sup>Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. <sup>68</sup>Division of Obstetrics and Gynaecology, School of Medicine, The University of Western Australia (UWA), Perth, Australia. <sup>69</sup>Channing Division of Network Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, USA. <sup>70</sup>Department of Internal Medicine, Henry Ford Health System, Detroit, MI, USA. <sup>71</sup>QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. <sup>72</sup>Population Health Research Institute, St George's, University of London, London, UK.

†These authors contributed equally to this work

#### Corresponding author

Klaus Bønnelykke, MD, PhD

COPSAC, Copenhagen Prospective Studies on Asthma in Childhood  
Herlev and Gentofte Hospital  
Ledreborg Allé 34  
2820 Gentofte  
Denmark  
Email: kb@copsac.com

## Introduction

Allergic rhinitis is the most common clinical presentation of allergy, affecting 400 million people worldwide, and with increasing incidence in westernized countries.<sup>1,2</sup> To elucidate the genetic architecture and understand disease mechanisms of allergic rhinitis, we carried out a meta-analysis of allergic rhinitis in 59,762 cases and 152,358 controls of European ancestry and identified a total of 41 risk loci for allergic rhinitis, including 20 loci not previously associated with allergic rhinitis, which were confirmed in a replication phase of 60,720 cases and 618,527 controls. Functional annotation implied genes involved in various immune pathways, and fine mapping of the HLA region suggested amino acid variants of importance for antigen binding. We further performed GWASs of allergic sensitization against inhalant allergens and non-allergic rhinitis suggesting shared genetic mechanisms across rhinitis-related traits. Future studies of the identified loci and genes might identify novel targets for treatment and prevention of allergic rhinitis.

## Main text

Allergic rhinitis (AR) is an inflammatory disorder of the nasal mucosa mediated by allergic hypersensitivity responses to environmental allergens<sup>1</sup> with large adverse effects on quality of life and health care expenditures. The underlying causes for AR are still not understood and prevention of the disease is not possible. The heritability of AR is estimated to be more than 65%<sup>3,4</sup>. Seven loci have been associated with allergic rhinitis in genome-wide association studies (GWAS) of AR per se, while other have been suggested from GWAS studies on related traits, such as self-reported allergy, asthma plus hay fever, or allergic sensitization<sup>5-9</sup>, but only few of these have been replicated.

We carried out a large-scale meta-GWAS of AR including a discovery meta-analysis of 16,531,985 genetic markers from 18 studies comprising 59,762 cases and 152,358 controls of primarily European ancestry (**Supplementary Table 1**, cohort recruitment details in **Supplementary Note**). We report the genetic heritability on the liability scale of AR as at least 7.8% (assuming 10% disease prevalence), with a genomic inflation of 1.048 (**Supplementary Figure 1**). We identified 42 genetic loci, with index markers below genomewide significance ( $p < 5 \times 10^{-8}$ ), of which 21 have previously been reported in relation to AR or other inhalant allergy<sup>6-9</sup> (**Fig. 1, Table 1, Table 2, Supplementary Fig. 2, Supplementary Fig. 3**).

One study (23andMe) had a proportionally large weight (~80%) in the discovery phase. Overall there was good agreement between 23andMe and the other studies with respect to effect size and direction, and regional association patterns (**Supplementary Table 2 and Supplementary Fig. 4+5**), and the genetic correlation was 0.80 ( $p < 2 \times 10^{-17}$ ). Heterogeneity between 23andMe and the remaining studies was statistically significant ( $p < 0.05$ ) for 7 of 42 loci, in most cases due to a smaller effect size in 23andMe. This was likely due to many non-23andMe studies using a more robust phenotype definition of doctor diagnosed AR (**Supplementary Table 3**), which tended to result in larger effect sizes (**Supplementary Table 4**).

The index markers from a total of 25 loci that had not previously been associated with AR or other inhalant allergy were carried forward to the replication phase. These included 16 loci that showed genome-wide significant association in the discovery phase and evidence of association ( $p < 0.05$ ) in both 23andMe and non-23andMe studies (**Supplementary Table 2**), and an additional 9 loci that were selected from the p-value stratum between  $5 \times 10^{-8}$  and  $1 \times 10^{-6}$  based on enrichment of gene sets involved in immune-signaling (**Supplementary Table 5**). Replication was sought in another 10 studies with 60,720 cases and 618,527 controls. Of the 25 loci, 20 loci reached a Bonferroni-corrected significance threshold of 0.05 ( $p < 0.0019$ ) in a meta-analysis of replication studies (**Fig. 1 (blue), Table 2**), and all of these reached genome-wide significance in the combined fixed-effect meta-analysis of discovery and replication studies (**Table 2**). Evidence of heterogeneity was seen for one of these loci (rs1504215), which did not reach statistical significance in the random effects model (0.95 [0.92; 0.97],  $p = 2.83 \times 10^{-7}$ , **Supplementary Fig. 3**).

A conditional analysis of top loci identified 13 additional independent variants at  $p < 1 \times 10^{-5}$ , with 4 of these being genome-wide significant (near *WDR36*, *HLA-DQB1*, *IL1RL1* and *LPP*) (**Supplementary Table 6** and **Supplementary Fig. 5**, bottom panel).

To gain insight into functional consequences of known and novel loci, we utilized a number of data sources, including 1) 11 eQTL sets and 1 meQTL set from blood and blood subsets; 2) 2 eQTL sets and 1 meQTL set from lung tissue; and 3) data on enhancer-promoter interactions in 15 different blood subsets. Support of regulatory effects on coding genes was found for 33 out of the 41 loci. Many loci showed evidence of regulatory effects across a wide range of immune cell types (including B- and T-cells), while other seemed cell type-specific (**Supplementary Table 7**). Calculation of the “credible set” of markers for each locus using a Bayesian approach that selects markers likely to contain the causal disease-associated markers (**Supplementary Table 8**) and looking up these in the Variant Effect Predictor database generated a list of 17 markers producing amino acid changes, including deleterious changes in NUSAP1, SULT1A1 and PLCL, as predicted by SIFT (**Supplementary Table 9**).

The major histocompatibility complex (MHC) on chr6p harbored some of the strongest association signals in the GWAS with independent signals located around *HLA-DQB* and *HLA-B*, respectively. The top variant at *HLA-DQB* was an eQTL for several HLA-genes, including *HLA-DQB1*, *HLA-DQA1*, *HLA-DQA2*, and *HLA-DRB1* in immune and/or lung tissue, and the top variant at *HLA-B* was an eQTL for *MICA* (**Supplementary Table 7**). In addition we found associations with several classical HLA alleles, including HLA-DQB1\*02:02, HLA-DQB1\*03:01, HLA-DRB1\*04:01, and HLA-C\*04:01, which were in weak LD ( $r^2 < 0.1$ ) with the GWAS top SNPs (**Supplementary Tables 10 and 11**), and strong associations with well imputed amino acid variants, including HLA-DQB1 His30 ( $p = 2.06 \times 10^{-28}$ , OR=0.91) and HLA-B AspHisLeu116 ( $p = 6.00 \times 10^{-13}$ , OR=1.06) (**Supplementary Tables 12 and 13**). Within HLA-DQB1, the amino acid variant was in moderate LD ( $r^2 = 0.71$ ) with the GWAS top SNP and accounted for most of the SNP association (rs34004019,  $p = 2.18 \times 10^{-28}$ , OR=0.88, conditional p-value= $1.35 \times 10^{-3}$ ). Within HLA-B, the strongest associated amino acid variant was only in weak LD ( $r^2 = 0.23$ ) with the top SNP and accounted for a small part of the SNP association (rs2428494,  $p = 3.99 \times 10^{-15}$ , OR=1.07, conditional p-value= $3.23 \times 10^{-10}$ ). Importantly, the strongest associated amino acid variants in HLA-DQB1 and HLA-B, respectively were both located in the peptide binding pockets with a

high likelihood of affecting MHC-peptide interaction (**Figure 2**). MHC class II molecules, including HLA-DQ, are known for their role in allergen-binding and Th2 driven immune responses<sup>10</sup> and our results therefore suggest that the GWAS signal at this locus involves structural changes related to allergen binding properties. This might be in addition to gene regulatory effects similar to what has been found for autoimmune disease.<sup>11,12</sup>

The majority of the 20 loci not previously associated with AR per se imply genes with a known role in the immune system, including IL7R<sup>13, 14</sup>, SH2B3<sup>15</sup>, CEBPA/CEBPG<sup>16, 17</sup>, CXCR5<sup>18</sup>, FCER1G, NFKB1<sup>19</sup>, BACH2<sup>20, 21</sup>, TYRO3<sup>22</sup>, LTK<sup>23</sup>, VPRBP<sup>24</sup>, SPPL3<sup>25</sup>, OASL<sup>26</sup>, RORA<sup>27</sup>, and TNFSF11<sup>28</sup>. Other loci imply genes with no clear function in AR pathogenesis. These include one of the strongest associated loci in this meta-analysis at 12q24.31 with the top-signal located between CDK2AP1 and C12orf65, harboring cis-eQTLs in blood and lung tissue for several genes and evidence for enhancer-promoter interaction with DDX55 in various immune cells. (**Supplementary Table 14** and further locus description in the **Supplementary Note**).

Concomitantly with the current study, a GWAS combining asthma, eczema and AR was conducted.<sup>29</sup> The majority (15/20) of identified AR loci in our study were also suggested in the previous, more unspecific, GWAS<sup>29</sup> (as indicated in Table 2), while many suggested loci from the previous GWAS were not identified in our study. Asthma, eczema and allergic rhinitis are related but distinct disease entities, often with separate disease mechanisms, e.g. allergic sensitization is present in only 50% of children with asthma<sup>30</sup> and 35% of children with eczema.<sup>31</sup> Our results therefore complement those from the less specific “atopic phenotype” GWAS<sup>29</sup> by pinpointing loci specifically associated, and replicated, in relation to allergic rhinitis.

AR loci were significantly enriched ( $p < 1e-5$ ) for variants reported to be associated with autoimmune disorders. Reported autoimmune variants were located within a 1mb distance of 31 (76%) of the 41 AR loci. For 24 of these, an autoimmune top SNP was also associated with AR, and for 12 of these the autoimmune top SNP was in LD ( $r^2 > 0.5$ ) with the AR top SNP (**Supplementary Table 15**). For approximately half of these, the direction of effect was the same for the autoimmune and AR top SNP in line with a previous study,<sup>32</sup> underlining the complex genetic relationship between AR and autoimmunity, which might involve shared as well as diverging molecular mechanisms.

Assessment of enrichment of AR-associated variant burden in open chromatin as defined by DNase hypersensitive sites showed a clear enrichment in several blood and immune cell subsets, with the largest enrichment in T-cells (CD3 expressing), B-cells (CD19 expressing), and T and NK-cells (CD56-expressing) (**Fig. 3, Supplementary Table 16, Supplementary Fig. 6**). We also probed tissue enrichment by means of gene expression data from a wide number of sources, showing enrichment of AR genes in blood and immune cell subsets, as well as in tissues of the respiratory system, including oropharynx, respiratory and nasal mucosa (**Supplementary Table 17**).

To explore biological connections and identify new pathways associated with AR, we combined all genes suggested from eQTL/meQTL analyses, enhancer-promoter interactions and localization within the top loci. The resultant prioritized gene set consisted of 255 genes, of which 89 (~36%) were present in more than one set (**Supplementary Fig. 7**). Overall, the full set was enriched for pathways involved in Th1 and Th2 Activation (**Fig. 4**), antigen presentation, cytokine signaling, and inflammatory responses (**Supplementary Table 18**).

Using the 255 prioritized genes in combination with STRING to identify proteins that interact with the proteins encoded by the high priority genes, we demonstrated a high degree of interaction at the protein level, and several of these proteins are target of approved drugs or drugs in development, including TNFSF11, NDUFAF1, PD-L1, IL-5, and IL-13 (**Fig. 4**).

AR is strongly correlated to allergic sensitization (presence of allergen-specific IgE), but sensitization is often present without AR suggesting specific mechanisms determining progression from sensitization to disease. We therefore conducted a GWAS on sensitization to inhalant allergens (AS) comprising 8,040 cases and 16,441 controls from 13 studies (**Supplementary Table 1**), making it the largest GWAS on allergic sensitization to date<sup>7</sup>. A total of 10 loci reached genome-wide significance, including one novel hit near the *FASLG* gene (**Supplementary Table 19**). The genetic heritability on the liability scale was 17.75% (10% prevalence), considerably higher than the heritability of AR in consistency with a more homogeneous phenotype. Look-up of AR top-loci in the AS GWAS demonstrated large agreement with 40 of the 41 AR markers showing same direction of effect and 28 also showing nominal significance for AS (**Supplementary Table 20**). This suggests that AR and AS share biological mechanisms and that AS loci generally affect systemic allergic sensitization. We compared genetic pathways of AR and AS using the DEPICT tool showing overlap in enriched pathways but also differences among the top gene sets, with AR gene sets characterized by B-cell, Th2, and parasite responses and AS gene sets characterized by a broader activation of cells (**Supplementary Fig 8 and Supplementary Tables 21 and 22**).

Non-allergic rhinitis, defined as rhinitis symptoms without evidence of allergic sensitization, is a common but poorly understood disease entity.<sup>33</sup> We performed the first GWAS on this phenotype hypothesizing that this might reveal specific rhinitis mechanisms. The analysis included 2,028 cases and 9,606 controls from 9 studies but did not identify any risk loci at the genome-wide significance level. Comparison with AR results suggested some overlap in susceptibility loci (**Supplementary Note and Supplementary Table 23**).

We estimated the proportion of AR in the general population that can be attributed to the 41 identified AR loci and obtained a conservative population-attributable risk fraction estimate of 39% (95% CI 26%-50%), considering the 10% of the population with the lowest genetic risk scores to represent an 'unexposed' group. Allergic rhinitis prevalence plotted by genetic risk score (**Supplementary Fig. 9**) showed approximately 2 times higher prevalence in the 7% of the population with the highest risk score compared to the 7% with the lowest risk score.

Finally, we investigated the genetic correlation of AR with AS, asthma<sup>34</sup>, and eczema<sup>35</sup> by LD score regression. There was a strong correlation between AR and AS ( $r^2=0.73$ ,  $p<2e-34$ ), moderate with asthma ( $r^2=0.60$ ,  $p<3e-14$ ) and weaker with eczema ( $r^2=0.40$ ,  $p<2e-07$ ).

The identified AR loci were tested for association with AR in non-European cohorts, only showing nominal significant association for a loci, but this analysis had limited statistical power due to population sizes (**Supplementary Table 24**).

In conclusion, we expanded the number of established susceptibility loci for AR and highlighted involvement of AR susceptibility loci in diverse immune cell types and both innate and adaptive IgE-related mechanisms. Future studies of novel AR loci might identify targets for treatment and prevention of disease.

276

## 277 Acknowledgments

278 Detailed acknowledgments and funding details are provided for each contributing study in the  
279 **Supplementary Note.**

280

## 281 Author contributions

282 Study design and management: K.B., J.W., M.S., D.P.S. Meta-analyses: M.S., J.W. Manuscript  
283 writing: K.B., J.W., M.S., J.A.C., J.T., L.E.J. M.A.F. Systems biology analyses: J.W., J.A.C., J.T.,  
284 L.E.J., J.M.M., S.B.-G., D.T. Data collection, analysis and design in the individual contributing  
285 studies: K.B., J.W., M.S., J.A.C., C.F., A. Abdellaoui, T.S.A., A. Alves, A.F.S.A., J.M.A, A.  
286 Arnold, A.B.-L., H. Baurecht, C.E.M.B., E.R.B, D.I.B., S. Bunyavanich, E.B., Z.C., I.C., A.C.,  
287 H.T.D., S.C.D., J.D., L.D., M.J.E., W.J.G., C.G., F.G., R.G., H.G., T.H., J. Heinrich, J.  
288 Henderson, N. H.-P., D.A.H., P.H., M.I., V.W.V.J., M.-R.J., D.L.J., I.J., M.K., J.K., A.K., Y.-A.L.,  
289 A.M.L., X.L., F.L.-D., E.M., D.A.M., R.M., D.L.N., E.A.N., T.P., L.P., C.E.P., G.P., M.P.-Y.,  
290 N.M.P.-H., F.R., A.S., K.S., J.S., G.S., E.T., P.J.T., C.T., M.T., J.Y.T., C.A.W., S.Weidinger,  
291 S.Weiss, G.W., L.K.W., C.O., M.A.F., H. Bisgaard, D.P.S. Immunological interpretation: N.S.,  
292 S.Brix. Gene expression analysis: M.G., J.D. Protein modeling: K.K.J.

293

## 294 Competing financial interests

295 G.S., I.J., and K.S. are affiliated with deCODE genetics/Amgen declare competing financial  
296 interests as employees. C.T., D.A.H., J.Y.T., and the 23andMe Research Team are employees  
297 of and hold stock and/or stock options in 23andMe, Inc. L.P. has received a fee for participating  
298 in a scientific input engagement meeting from Merck Sharp & Dohme Limited, outside of the  
299 submitted work.

300

## 301 References

- 302 1. Greiner, A. N., Hellings, P. W., Rotiroti, G. & Scadding, G. K. Allergic rhinitis. *Lancet* **378**,  
303 2112–2122 (2011).
- 304 2. Björkstén, B. *et al.* Worldwide time trends for symptoms of rhinitis and conjunctivitis: Phase  
305 III of the International Study of Asthma and Allergies in Childhood. *Pediatr. Allergy*  
306 *Immunol.* **19**, 110–124 (2008).



- 307 3. Willemsen, G., van Beijsterveldt, T. C. E. M., van Baal, C. G. C. M., Postma, D. &  
308 Boomsma, D. I. Heritability of self-reported asthma and allergy: a study in adult Dutch  
309 twins, siblings and parents. *Twin Res. Hum. Genet.* **11**, 132–142 (2008).
- 310 4. Fagnani, C. *et al.* Heritability and shared genetic effects of asthma and hay fever: an Italian  
311 study of young twins. *Twin Res. Hum. Genet.* **11**, 121–131 (2008).
- 312 5. Ramasamy, A. *et al.* A genome-wide meta-analysis of genetic variants associated with  
313 allergic rhinitis and grass sensitization and their interaction with birth order. *J. Allergy Clin.*  
314 *Immunol.* **128**, 996–1005 (2011).
- 315 6. Hinds, D. A. *et al.* A genome-wide association meta-analysis of self-reported allergy  
316 identifies shared and allergy-specific susceptibility loci. *Nat. Genet.* **45**, 907–911 (2013).
- 317 7. Bønnelykke, K. *et al.* Meta-analysis of genome-wide association studies identifies ten loci  
318 influencing allergic sensitization. *Nat. Genet.* **45**, 902–906 (2013).
- 319 8. Ferreira, M. A. R. *et al.* Genome-wide association analysis identifies 11 risk variants  
320 associated with the asthma with hay fever phenotype. *J. Allergy Clin. Immunol.* **133**, 1564–  
321 1571 (2014).
- 322 9. Bunyavanich, S. *et al.* Integrated genome-wide association, coexpression network, and  
323 expression single nucleotide polymorphism analysis identifies novel pathway in allergic  
324 rhinitis. *BMC Med. Genomics* **7**, 48 (2014).
- 325 10. Jahn-Schmid, B., Pickl, W. F. & Bohle, B. Interaction of Allergens, Major Histocompatibility  
326 Complex Molecules, and T Cell Receptors: A ‘Ménage à Trois’ That Opens New Avenues  
327 for Therapeutic Intervention in Type I Allergy. *Int. Arch. Allergy Immunol.* **156**, 27–42  
328 (2011).
- 329 11. Cavalli, G. *et al.* MHC class II super-enhancer increases surface expression of HLA-DR  
330 and HLA-DQ and affects cytokine production in autoimmune vitiligo. *Proc. Natl. Acad. Sci.*  
331 *U. S. A.* **113**, 1363–1368 (2016).

12. Hayashi, M. *et al.* Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A\*02:01 in vivo. *Proc. Natl. Acad. Sci. U. S. A.* **113**, 1357–1362 (2016).
13. Puel, A., Ziegler, S. F., Buckley, R. H. & Leonard, W. J. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. *Nat. Genet.* **20**, 394–397 (1998).
14. Lundmark, F. *et al.* Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. *Nat. Genet.* **39**, 1108–1113 (2007).
15. Mori, T. *et al.* Lnk/Sh2b3 controls the production and function of dendritic cells and regulates the induction of IFN- $\gamma$ -producing T cells. *J. Immunol.* **193**, 1728–1736 (2014).
16. Scott, L. M., Civin, C. I., Rorth, P. & Friedman, A. D. A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. *Blood* **80**, 1725–1735 (1992).
17. Gao, H., Parkin, S., Johnson, P. F. & Schwartz, R. C. C/EBP gamma has a stimulatory role on the IL-6 and IL-8 promoters. *J. Biol. Chem.* **277**, 38827–38837 (2002).
18. León, B. *et al.* Regulation of T(H)2 development by CXCR5+ dendritic cells and lymphotoxin-expressing B cells. *Nat. Immunol.* **13**, 681–690 (2012).
19. Lawrence, T. The nuclear factor NF-kappaB pathway in inflammation. *Cold Spring Harb. Perspect. Biol.* **1**, a001651 (2009).
20. Shinnakasu, R. *et al.* Regulated selection of germinal-center cells into the memory B cell compartment. *Nat. Immunol.* **17**, 861–869 (2016).
21. Roychoudhuri, R. *et al.* BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers. *Nat. Immunol.* **17**, 851–860 (2016).
22. Rothlin, C. V., Ghosh, S., Zuniga, E. I., Oldstone, M. B. A. & Lemke, G. TAM receptors are pleiotropic inhibitors of the innate immune response. *Cell* **131**, 1124–1136 (2007).
23. Chan, P. Y. *et al.* The TAM family receptor tyrosine kinase TYRO3 is a negative regulator

of type 2 immunity. *Science* **352**, 99–103 (2016).

24. Kassmeier, M. D. *et al.* VprBP binds full-length RAG1 and is required for B-cell development and V(D)J recombination fidelity. *EMBO J.* **31**, 945–958 (2012).
25. Hamblet, C. E., Makowski, S. L., Tritapoe, J. M. & Pomerantz, J. L. NK Cell Maturation and Cytotoxicity Are Controlled by the Intramembrane Aspartyl Protease SPPL3. *J. Immunol.* **196**, 2614–2626 (2016).
26. Andersen, J. B., Strandbygård, D. J., Hartmann, R. & Justesen, J. Interaction between the 2'-5' oligoadenylate synthetase-like protein p59 OASL and the transcriptional repressor methyl CpG-binding protein 1. *Eur. J. Biochem.* **271**, 628–636 (2004).
27. Halim, T. Y. F. *et al.* Retinoic-acid-receptor-related orphan nuclear receptor alpha is required for natural helper cell development and allergic inflammation. *Immunity* **37**, 463–474 (2012).
28. Anderson, D. M. *et al.* A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. *Nature* **390**, 175–179 (1997).
29. Ferreira, M. A. *et al.* Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. *Nat. Genet.* **49**, 1752–1757 (2017).
30. Pearce, N., Pekkanen, J. & Beasley, R. How much asthma is really attributable to atopy? *Thorax* **54**, 268–272 (1999).
31. Bohme, M., Wickman, M., Lennart Nordvall, S., Svartengren, M. & Wahlgren, C. F. Family history and risk of atopic dermatitis in children up to 4 years. *Clin. Exp. Allergy* **33**, 1226–1231 (2003).
32. Kreiner, E. *et al.* Shared genetic variants suggest common pathways in allergy and autoimmune diseases. *J. Allergy Clin. Immunol.* (2017). doi:10.1016/j.jaci.2016.10.055
33. Bousquet, J. *et al.* Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. *Allergy* **63**, 842–853 (2008).

34. Moffatt, M. F. *et al.* Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. *Nature* **448**, 470–473 (2007).
35. Paternoster, L. *et al.* Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. *Nat. Genet.* **47**, 1449–1456 (2015).

390

## 391 Figure legends

### 392 **Figure 1: Manhattan plot of the meta-GWAS discovery phase**

393 Circular plot of p-values from a inverse variance weighted fixed-effect meta-analysis of  
394 association of 16,531,985 genetic markers to allergic rhinitis from the discovery phase, including  
395 212,120 individuals. Only markers with  $p < 1e-3$  are shown. Labels indicate nearest gene name  
396 for index marker in locus (marker with lowest p-value). Green labels indicate loci previously  
397 associated with allergy; blue labels indicate novel AR loci; grey labels indicate novel loci that  
398 were not carried forward to the replication phase. Green line indicates level of genome wide  
399 significance ( $p = 5e-8$ ).

400

### 401 **Figure 2: Structural visualization of amino acid variants associated with allergic rhinitis**

402 The surface of the MHC molecule is shown in white, while the backbone of the bound peptide is  
403 shown in dark gray. The amino acid variant in focus is highlighted in red and the peptide binding  
404 pockets of the MHC molecule is indicated with dashed circles and annotated P1-P9. (A) The  
405 amino acid variant with strongest association to AR is HLA-DQB1 His30 (MHC class II), located  
406 close to P6 with a distance of 6Å to the peptide (excluding the peptide side chain). The  
407 protective amino acid variant at this location in relation to AR is histidine, whereas the risk  
408 variant is serine. Histidine is positively charged and has a large aromatic ring, whereas serine is  
409 not charged and not aromatic. Therefore, this mutation results in a significant change of the  
410 binding pocket environment. (B) The strongest AR-associated amino acid variation in HLA-B  
411 (MHC class I) is HLA-B AspHisLeu116, located close to P9 with a distance of 7Å to the peptide  
412 (excluding the peptide side chain). The close proximity to the bound peptide for both variants  
413 indicates that they are likely to affect the MHC-peptide interaction and thereby which peptides  
414 are presented.

415

### 416 **Figure 3: Enrichment of allergic rhinitis-associated variants in tissue-specific open 417 chromatin**

418 Enrichment of 16,531,985 genetic variants associated with allergic rhinitis in 212,120 individuals  
419 (at  $p < 1e-08$  as threshold for marker association) in 189 cell types from ENCODE and  
420 Roadmap epigenomics data. Enrichment and p-value was calculated empirically against a  
421 permuted genomic background using the GARFIELD tool. Red labels indicate blood and blood-  
422 related cell-types, grey labels indicate other cell types. Due to number of permutations =  $1e7$ ,  
423 empirical p-values reached a minimum ceiling of  $1/1e7$ . FDR threshold = 0.00026. For Epstein-  
424 Barr virus transformed B-lymphocyte cell types (cell type "GM\*\*\*\*"), only most enriched instance  
425 is shown ("B-Lymphocyte"). NHEK = normal human epidermal keratinocytes, HMEC/vHMEC =  
426 mammary epithelial cells, HCM = human cardiac myocytes, WI-38 = lung fibroblast-derived,

427 HRGEC = human renal glomerular endothelial cell, HCFaa = Human Cardiac Fibroblasts-Adult  
428 Atrial cell, HMVEC-dBI-Neo = human microvascular endothelial cells, Th1 = T helper cell, type  
429 1, Th2 = T helper cell, type 2.

430  
431 **Figure 4: Interaction network between drugs and proteins from genes associated with**  
432 **allergic rhinitis**  
433 Grey nodes represent locus genes as well as genes prioritized from e/meQTL and PCHiC  
434 sources, based on genetics association of 16,531,985 markers with allergic rhinitis in 212,120  
435 individuals. Blue nodes represent drugs from the ChEMBL drug database. Edges represent  
436 very-high confidence interactions from the STRING database (for locus-locus interactions) and  
437 drug target evidence (for drug-locus interactions). Red borders indicate genes with protein  
438 products that were significantly enriched in the “Th1 and Th2 Activation” pathway (-log[p-value]  
439 >19.1) from the IPA pathway analysis.  
440

**Table 1.** Association results of index markers (variant with lowest p-value for each locus) previously reported in relation to AR or other inhalant allergy. Column “Nearest gene” denotes nearest up- and downstream gene (for intergenic variants with two genes listed), or surrounding gene (for intronic variants with one gene listed), with the exception of rs5743618, an exonic missense variant within *TLR1*. EA/OA=effect allele/other allele. P-value is calculated from the logistic regression model. Het.P=p-value for heterogeneity obtained from Cochrane’s Q test.

Variant	Locus	Nearest genes	EA/OA	Discovery					
				EAF	n (studies)	OR	95% conf.int	P	Het. P
Known									
rs34004019	6p21.32	HLA-DQB1;HLA-DQA1	G/A	0.27	196,951 (11)	0.89	0.87-0.90	1.00E-30	0.41
rs950881	2q12.1	IL1RL1;IL1RL1	T/G	0.15	212,120 (18)	0.88	0.87-0.90	1.74E-30	0.91
rs5743618	4p14	TLR1;TLR10	A/C	0.27	210,652 (17)	0.90	0.89-0.92	4.38E-27	0.70
rs1438673	5q22.1	CAMK4;WDR36	C/T	0.50	212,120 (18)	1.08	1.07-1.10	3.15E-26	0.26
rs7936323	11q13.5	LRR32;C11orf30	A/G	0.48	212,120 (18)	1.08	1.06-1.09	6.53E-24	0.0001
rs2428494	6p21.33	HLA-B;HLA-C	A/T	0.42	195,753 (12)	1.08	1.06-1.09	7.01E-19	0.25
rs11644510	16p13.13	RMI2;CLEC16A	T/C	0.37	212,120 (18)	0.93	0.92-0.95	1.58E-17	0.65
rs12939457	17q12	GSDMB;ZPBP2	C/T	0.44	212,120 (18)	0.94	0.92-0.95	2.35E-17	0.02
rs148505069	4q27	IL21;IL2	G/A	0.33	212,120 (18)	1.07	1.05-1.08	2.54E-15	0.02
rs13395467	2p25.1	ID2;RNF144A	G/A	0.28	212,120 (18)	0.94	0.92-0.95	9.93E-15	0.61
rs9775039	9p24.1	IL33;RANBP6	A/G	0.16	212,120 (18)	1.08	1.06-1.10	2.22E-14	0.40
rs2164068	2q33.1	PLCL1	A/T	0.49	212,120 (18)	0.94	0.93-0.96	4.21E-14	0.82
rs2030519	3q28	TPRG1;LPP	G/A	0.49	212,120 (18)	1.06	1.04-1.07	1.83E-13	0.12
rs11256017	10p14	CELF2;GATA3	T/C	0.18	212,120 (18)	1.07	1.05-1.09	2.72E-12	0.60
rs17294280	15q22.33	AAGAB;SMAD3	G/A	0.25	212,120 (18)	1.07	1.05-1.09	5.97E-12	0.07
rs7824993	8q21.13	ZBTB10;TPD52	A/G	0.37	212,120 (18)	1.05	1.04-1.07	1.86E-10	0.56
rs9282864	16p11.2	SULT1A1;SULT1A2	C/A	0.33	208,761 (16)	0.94	0.93-0.96	4.69E-10	0.03
rs9687749	5q31.1	IL13;RAD50	T/G	0.44	207,604 (16)	1.06	1.04-1.09	1.84E-09	0.19
rs61977073	14q21.1	TTC6	G/A	0.22	212,120 (18)	1.06	1.04-1.08	5.78E-09	0.05
rs6470578	8q24.21	TMEM75;MYC	T/A	0.28	212,120 (18)	1.05	1.03-1.07	4.36E-08	0.02
rs3787184	20q13.2	NFATC2;KCNG1	G/A	0.19	207,604 (16)	0.94	0.93-0.96	4.76E-08	0.69

**Table 2.** Association results of index markers (variant with lowest p-value for each locus) not previously associated with AR reaching a Bonferroni-corrected significance threshold of 0.05 in the replication phase. Column “Nearest gene” denotes nearest up- and downstream gene (for intergenic variants with two genes listed), or surrounding gene (for intronic variants with one gene listed), with the exception of rs1504215, an exonic synonymous variant within *BACH2*. EA/OA=effect allele/other allele. P-value is calculated from the logistic regression model. Het.P=p-value for heterogeneity obtained from Cochrane’s Q test. \* Variants also reported associated with a combined asthma/eczema/hay fever phenotype by Ferreira et al.<sup>29</sup> (within +/- 1Mb).

Variant	Locus	Nearest genes	EA/OA	Discovery						Replication						Combined			
				EAF	n (studies)	OR	95% conf.int	P	Het. P	n (studies)	OR	95% conf.int	P	FWER	n (studies)	OR	95% conf.int	P	Het. P
rs7717955*	5p13.2	CAPSL; IL7R	T/C	0.27	212,120 (18)	0.95	0.93-0.96	1.50E-09	0.24	679,247 (10)	0.93	0.91-0.94	4.09E-25	1.06E-23	891,367 (28)	0.94	0.93-0.95	3.78E-32	0.09
rs63406760*	12q24.31	CDK2AP1; C12orf65	G/-	0.26	210,652 (17)	0.93	0.91-0.95	5.12E-14	0.91	675,338 (7)	0.95	0.93-0.96	3.27E-12	8.51E-11	885,990 (24)	0.94	0.93-0.95	2.54E-24	0.89
rs1504215*	6q15	BACH2; GJA10	A/G	0.34	207,604 (16)	0.95	0.94-0.97	1.49E-08	0.02	679,247 (10)	0.95	0.94-0.97	1.99E-11	5.17E-10	886,851 (26)	0.95	0.94-0.96	1.54E-18	0.05
rs28361986*	11q23.3	CXCR5; DDX6	A/T	0.20	212,120 (18)	0.93	0.91-0.95	1.81E-14	0.87	675,919 (8)	0.94	0.93-0.96	7.92E-11	2.06E-09	888,039 (26)	0.94	0.92-0.95	2.32E-23	0.91
rs2070902*	1q23.3	ALS90714.1; FCER1G	T/C	0.25	212,120 (18)	1.06	1.04-1.08	1.03E-10	0.18	679,247 (10)	1.05	1.03-1.06	7.27E-10	1.89E-08	891,367 (28)	1.05	1.04-1.06	6.19E-19	0.23
rs111371454*	15q15.1	ITPKA; RTF1	G/A	0.21	212,120 (18)	1.06	1.03-1.08	1.65E-07	0.17	675,338 (7)	1.04	1.03-1.06	8.47E-09	2.20E-07	887,458 (25)	1.05	1.03-1.06	1.28E-14	0.22
rs12509403*	4q24	MANBA; NFKB1	T/C	0.32	212,120 (18)	0.95	0.94-0.97	9.97E-09	0.27	679,247 (10)	0.96	0.95-0.97	1.86E-08	4.84E-07	891,367 (28)	0.96	0.95-0.97	1.17E-15	0.39
rs9648346*	7p15.1	JAZF1; TAX1BP1	G/C	0.22	207,604 (16)	1.05	1.03-1.07	3.62E-08	0.74	679,247 (10)	1.04	1.03-1.06	1.39E-07	3.63E-06	886,851 (26)	1.05	1.03-1.06	3.30E-14	0.48
rs35350651*	12q24.12	ATXN2; SH2B3	C/-	0.49	206,136 (15)	1.04	1.03-1.06	6.63E-08	0.60	672,701 (6)	1.04	1.02-1.05	1.41E-07	3.66E-06	878,837 (21)	1.04	1.03-1.05	5.82E-14	0.43
rs2519093*	9q34.2	ABO; OBP2B	T/C	0.20	212,120 (18)	1.06	1.04-1.09	4.96E-11	0.38	675,919 (8)	1.04	1.03-1.06	2.96E-07	7.68E-06	888,039 (26)	1.05	1.04-1.07	2.79E-16	0.61
rs62257549	3p21.2	VPRBP	A/G	0.20	212,120 (18)	0.95	0.93-0.97	7.13E-08	0.45	677,615 (9)	0.96	0.94-0.97	3.37E-07	8.76E-06	889,735 (27)	0.95	0.94-0.97	1.84E-13	0.53
rs11677002	2p23.2	FOSL2; RBKS	C/T	0.45	212,120 (18)	0.96	0.95-0.98	3.80E-07	0.21	679,247 (10)	0.97	0.96-0.98	3.54E-07	9.20E-06	891,367 (28)	0.97	0.96-0.97	7.08E-13	0.36
rs35597970*	10q24.32	ACTR1A; TMEM180	-/A	0.45	210,652 (17)	1.06	1.04-1.07	1.34E-13	0.96	676,970 (8)	1.03	1.02-1.05	4.37E-07	1.14E-05	887,622 (25)	1.04	1.03-1.05	5.42E-18	0.53
rs2815765	1p31.1	LRRIQ3; NEGR1	T/C	0.37	212,120 (18)	0.95	0.94-0.97	1.18E-09	0.59	679,247 (10)	0.97	0.95-0.98	6.16E-07	1.60E-05	891,367 (28)	0.96	0.95-0.97	9.45E-15	0.52
rs11671925*	19q13.11	CEBPA; SLC7A10	A/G	0.17	206,136 (15)	0.94	0.92-0.96	1.80E-08	0.97	677,551 (9)	0.96	0.94-0.98	2.80E-06	7.29E-05	883,687 (24)	0.95	0.94-0.96	5.91E-13	0.60
rs2461475*	12q24.31	SPPL3; ACADS	C/T	0.47	212,120 (18)	1.04	1.02-1.05	9.19E-07	0.97	677,551 (9)	1.03	1.02-1.04	6.52E-06	0.0002	889,671 (27)	1.03	1.02-1.04	3.81E-11	0.83
rs6738964*	2q36.3	SPHKAP; DAW1	G/T	0.24	212,120 (18)	0.96	0.94-0.97	4.51E-07	0.72	679,247 (10)	0.97	0.96-0.98	4.96E-05	0.0013	891,367 (28)	0.96	0.95-0.97	1.86E-10	0.87
rs10519067*	15q22.2	RORA	A/-	0.13	212,120 (18)	0.93	0.91-0.96	1.78E-09	0.37	442,354 (7)	0.93	0.90-0.96	7.53E-05	0.0020	654,474 (25)	0.93	0.92-0.95	5.53E-13	0.36
rs138050288*	1p36.23	RERE; SLC45A1	-/CA	0.29	210,652 (17)	1.05	1.04-1.07	5.96E-10	0.71	675,338 (7)	1.03	1.01-1.04	0.0002	0.0046	885,990 (24)	1.04	1.03-1.05	6.62E-12	0.63
rs7328203	13q14.11	TNFSF11; AKAP11	G/T	0.46	212,120 (18)	1.05	1.03-1.06	5.94E-09	0.90	677,551 (9)	1.02	1.01-1.04	0.0005	0.0134	889,671 (27)	1.03	1.02-1.04	1.28E-10	0.78



## Methods:

### Phenotype definition

#### Allergic rhinitis (AR)

Cases were defined as individuals ever having a diagnosis or symptoms of AR dependent on available phenotype definitions in the included studies (**Supplementary Table 3** and cohort recruitment details in **Supplementary Note**). All relevant ethical regulations were followed as specified in relation to the individual studies in the **Supplementary Note**. To maximize numbers and optimize statistical power, we did not require doctor-diagnosed AR or verification by allergic sensitization. This approach was confirmed by a sensitivity analysis in 23andMe based on association with known risk loci for allergic rhinitis (data not shown). Controls were defined as individuals who never had a diagnosis or symptoms of AR.

#### Allergic sensitization (AS)

We considered specific IgE production against inhalant allergens without restriction by assessment method or type of inhalant allergen. Cases were defined as individuals with objectively measured sensitization against at least one of the inhalant allergens tested for in the respective studies, and controls were defined as individuals who were not sensitized against any of the allergens tested for. We included sensitization assessed by skin reaction after puncture of the skin with a droplet of allergen extract (SPT) and/or by detection of the levels of circulating allergen-specific IgE in the blood. The SPT wheal diameter cutoffs were 3 mm larger than the negative control for cases and smaller than 1 mm for controls. To optimize case specificity and the correlation between methods, we chose a high cutoff of specific IgE levels for cases (0.7 IU/ml) and a low cutoff for controls (0.35 IU/ml).

#### Non-allergic rhinitis (NAR)

Cases were defined as individuals with current allergic rhinitis symptoms (within the last 12 months) and no allergic sensitization (negative specific IgE ( $< 0.35$  IU/mL) and/or negative skin prick test ( $< 1$  mm) for all allergens and time points tested)

Controls were defined as individuals never having symptoms of allergic rhinitis and no allergic sensitization (negative specific IgE ( $< 0.35$  IU/mL) and/or negative skin prick test ( $< 1$  mm) for all allergens and time points tested)

For all 3 phenotypes, we combined data from children and adults but chose a lower age limit of 6 years, as allergic rhinitis and sensitization status at younger ages show poorer correlation with status later in life, both owing to transient symptoms/sensitization status and frequent development of symptoms/sensitization during late childhood.

### GWAS QC and cohort summary data harmonization

For AR, AS, and NAR, each cohort imputed their data separately using the 1000 Genomes Project (1KGP) phase 1, version 3 release, and conducted the genome-wide association

analysis adjusted for sex and if necessary for age and principal components (**Supplementary Table 3**). All studies included individuals of European descent, except Generation R and RAINE, comprising a mixed, multi-ethnic population. We utilized EasyQC v. 9.2<sup>36</sup> for quality control and marker harmonization for cohort-level meta-GWAS summary files. Cohort data was harmonized to genome build GRCh37 and checked against 1KGP phase 3 reference allele frequencies for processing problems. GWAS summary “karyograms” were visually inspected to catch cohorts with incomplete data. Distributions of estimate coefficients and errors, as well as “Standard error vs. sample size”- and “p value vs. z-score” plots were inspected for each cohort for systematic errors in statistical models. Ambiguous markers that were non-unique in terms of both genomic position and allele coding were removed. A minimum imputation score of 0.3 ( $R^2$ ) or 0.4 (proper\_info) was required for markers. A minimum minor allele count of 7 was required for each marker in each cohort, as suggested by the GIANT consortium and EasyQC.

## Meta-Analysis

For AR, AS, and NAR, meta-analysis for the discovery phase was conducted using GWAMA<sup>37</sup> with an inverse variance weighted fixed-effect model with genomic control correction of the individual studies. Each locus is represented by the variant showing the strongest evidence within a 1Mb buffer. Loci were inspected visually by plotting genomic neighbourhood and coloring for 1KGP  $r^2$  values. From the pool of genomewide significant markers in the discovery, one locus with index marker rs193243426 without a credible LD structure was removed from further analysis (**Supplementary Fig. 10**). Heterogeneity was assessed with Cochran’s Q test. Meta-analysis of replication candidates from the AR discovery phase was carried out using R version 3.4.0, and the *meta* package version 4.8-2 with an inverse variance weighted fixed-effect model. For a subset of markers, cohorts reported suitable proxies ( $r^2 > 0.85$ ), where followed-up markers were not present or had insufficient imputation or genotyping quality (**Supplementary Table 25**).

## Gene set overrepresentation analysis, discovery phase

To facilitate selection of biologically relevant discovery candidates in the sub-genomewide significant stratum ( $5e-8 < p < 1e-6$ ), we employed a custom gene set overrepresentation analysis algorithm implemented in R, with a scoring and permutation regime modeled after MAGENTA.<sup>38</sup> Genes with lengths less than 200bp, with copies on multiple chromosomes, and with multiple copies on the same chromosome more than 1Mb apart were removed from analysis. Gene models (GENCODE v 19) were downloaded from the UCSC Table Browser,<sup>39</sup> and expanded 110 kb upstream, and 40 kb downstream, similar to MAGENTA. The HLA region was excluded from analysis (chromosome 6: 29,691,116-33,054,976). Similar to MAGENTA, gene scores were adjusted for number of markers per gene, gene width, recombination hotspots, genetic distance, and number of independent markers per gene, all with updated data from UCSC Table Browser. For the gene set overrepresentation permutation calculation, gene sets from the MSigDB collections c2, c3, c5, c7, and hallmark, were included.<sup>40</sup> A MAGENTA-style enrichment cutoff at 95% was used. Gene sets with  $FDR < 0.05$  were considered.

## Conditional analyses

To identify additional independent markers at each discovery genomic region, we used Genome-wide Complex Trait Analysis (GCTA) v. 1.26.0.<sup>41</sup> Within a window of +/- 1Mb of each discovery phase index marker, all markers were conditioned on the index using the --cojo-cond feature of GCTA with default parameters. Plink v. 1.90b3.42<sup>42</sup> was used to calculate  $r^2$  for GCTA with the UK10K full genotype panel<sup>43</sup> as reference. A total of 42 of 52 markers from the full discovery phase were present in UK10K. As a MAF-dependent inflation of conditional p-values was observed (data not shown), only conditional markers with MAF  $\geq 10\%$  were selected.

## Locus definition and credible sets for VEP annotation

Discovery loci were defined as index markers extended with markers in LD ( $r^2 \geq 0.5$ ), based on the 1KGP phase 3. Protein coding gene transcript models (GENCODE v. 24) were downloaded from the UCSC Table Browser, and nearest upstream, downstream, as well as all genes within the extended loci were annotated.

Credible sets for each locus were calculated using the method of Morris, A.P.<sup>44</sup>.

LD was calculated for each discovery index variant within +/- 500 kb, and markers with  $r^2 < 0.1$  were excluded. For the remaining markers, the Bayesian Factor (ABF) values and the posterior probabilities (PostProb) were calculated, and cumulative posterior probability values were generated based ranking markers on ABF. Finally, variants were included in the 99% credible set until the cumulative posterior probability was greater or equal than 0.99.

Credible sets for each loci was annotated with information on mutation impact in coding regions using the Variant effect Prediction (VeP) REST API<sup>45</sup>, exporting only the nonsynonymous substitutions.

## GWAS catalogue lookup

For annotation of markers with identification in previous GWA studies, the GWAS catalog was downloaded from NHGRI-EBI (v.1.0.1, 2016-11-28). For this analysis, AR loci were lifted from genomic build GRCh37 to GRCh38, and extended with +/- 1Mb in each direction before being overlapped with GWAS catalog annotations. Relevant GWAS catalog overlap traits were binned into trait groups "Allergic Rhinitis", "Asthma", "Autoimmune", "Eczema", "Infectious Diseases", "Lung-related Traits", and "Other allergy". A million random genomic intervals of the same length (2Mb) were obtained to generate a background overlap distribution, and p-values were calculated from this background.

## HLA classical allele analysis

Analyses of imputed classical HLA-alleles were performed in the 23andMe study (AR discovery population) comprising 49,180 individuals with allergic rhinitis and 124,102 controls.

HLA imputation was performed with HIBAG v. 1.2.3.<sup>46</sup> We imputed allelic dosage for HLA-A, B, C, DPB1, DQA1, QB1, and DRB1 loci at four-digit resolution using the default settings of HIBAG for a total of 292 classical HLA alleles.

Using an approach suggested by P. de Bakker,<sup>47</sup> we downloaded the files that map HLA alleles to amino acid sequences from <https://www.broadinstitute.org/mpg/snp2hla/> and mapped our imputed HLA alleles at four-digit resolution to the corresponding amino acid sequences; in this way we translated the imputed HLA allelic dosages directly to amino acid dosages. We encoded all amino acid variants in the 23andMe European samples as 2395 bi-allelic amino acid polymorphisms as previously described.<sup>48</sup>

Similar to the SNP imputation, we measured imputation quality using  $r^2$ , which is the ratio of the empirically observed variance of the allele dosage to the expected variance assuming Hardy-Weinberg equilibrium.

To test associations between imputed HLA alleles, amino acid variants, and phenotypes, we performed logistic regression using the same set of covariates used in the SNP-based GWAS. We applied a forward stepwise strategy, within each type of variant, to establish statistically independent signals in the HLA region. Within each variant type, we first identified the most strongly associated signals (lowest p-value) and performed forward iterative conditional regression to identify other independent signals. All analyses were controlled for sex and five principal components of genetic ancestry. The p-values were calculated using a likelihood ratio test.

## Structural visualization of amino acid variants

Structural visualization of amino acid variants was performed for the strongest associated variants in HLA-DQB1 (position 30) and HLA-B (position 116), respectively (**Supplementary Table 10**) and were made using X-ray structures from the Protein Data Bank (PDB).<sup>49</sup> To find the best structure we used the specialized search function in the Immune Epitope Database,<sup>50</sup> selecting only X-ray crystalized structures for the specific MHC classes HLA-DQB1 (class II) and HLA-B (class I). Using this criterion, we found 17 crystallized structures for HLA-DQB1 and 164 structures for HLA-B. From these lists, we selected the structure with the lowest resolution and the amino acids encoded by the reported top SNPs. The PDB accession code for the selected structures was 4MAY<sup>51</sup> for HLA-DQB1 and 2A83<sup>52</sup> for HLA-B and both structures were visualized using PyMOL v. 1.8.2.1 (<http://www.pymol.org>). Furthermore, we used PyMOL to measure intra-molecular distances from the side chain of the amino acids associated with allergic rhinitis to the C $\alpha$  atoms in the peptide. This distance measure was chosen to accommodate the possibility for different amino acids in the peptide. In order for two amino acids to interact the distance should be approximately 4Å or less. We measured distances of 6Å (HLA-DQB1) and 7Å (HLA-B). However these distances do not include the peptide side chains which range from 1.5 Å – 8.8 Å. Therefore, we estimate that physical interaction between the amino acids encoded by the top SNPs and the peptide is likely.

## Genetic heritability and genetic correlation

For calculating genetic heritability and genetic correlation between AR and AS, as well as between clinical cohorts and 23andMe within AR, we utilized the LD score regression based method as implemented by LDSC v. 1.0.<sup>45,53</sup> Population prevalence was set to 10% for AR and

AS. Genetic correlation analysis between AR, AS and published GWAS studies was carried out using the LDHUB platform v. 1.3.1<sup>54</sup> against all traits, but excluding Metabolites<sup>55</sup>.

## eQTL sources and analysis

From GTEx V6p<sup>56</sup>, all significant variant-gene cis eQTL pairs for whole blood, lung, and EBV-transformed lymphocytes were downloaded from <https://gtexportal.org>, and carried forward in analysis. From Westra et al.<sup>57</sup>, both cis and trans eQTLs in whole blood were downloaded, and variant-gene pairs with FDR < 0.1 were carried forward in analysis. From Fairfax et al.<sup>58</sup>, cis eQTLs from monocytes and B cells were downloaded, and variant-gene pairs with FDR < 0.1 were carried forward in analyses. From Bonder et al.<sup>58</sup>, meQTLs from whole blood were downloaded, and variant-probe pairs with FDR < 0.05 were carried forward in analyses. From Nicodemus-Johnson et al.<sup>59</sup>, cis eQTLs and meQTLs from lung were downloaded, and variant-gene pairs with FDR < 0.1 were carried forward in analyses. From Momozawa et al. [in press, personal correspondence], cis eQTLs from blood cell types CD14, CD15, CD19, CD4, and CD8 were downloaded, and variant-gene pairs with a weighted correlation of  $\geq 0.6$  were carried forward to analysis. For supplementary table 14 priority genes, protein coding information was downloaded from the UCSC Table Browser, using the “transcriptClass” field from the “wgEncodeGencodeAttrsV24lift37” table.

## Promoter Capture Hi-C Gene Prioritisation

To assess spatial promoter interactions in the discovery set, we performed a Capture Hi-C Gene Prioritisation (CHIGP) as described in Javierre et al.<sup>60</sup> and <https://github.com/ollyburren/CHIGP> using recommended settings and data sources: 0.1cM recombination blocks, 1KGP EUR reference population, coding markers from the GRCh37 Ensembl assembly and the CHICAGO-generated<sup>61</sup> Promoter Capture Hi-C peak matrix data from 17 human primary blood cell types supplied in the original paper. The resulting protein-coding prioritized genes (gene score > 0.5) were used in the downstream network analysis, from cell types "Fetal thymus", "Total CD4 T cells", "Activated total CD4 T cells", "Non-activated total CD4 T cells", "Naive CD4 T cells", "Total CD8 T cells", "Naive CD8 T cells", "Total B cells", "Naive B cells", "Endothelial precursors", "Macrophages M0", "Macrophages M1", "Macrophages M2", "Monocytes", and "Neutrophils".

## Gene set overrepresentation analysis of known and replicating novel loci

All high-confidence gene symbols from eQTL and meQTL sources, PCHiC, as well as genes (models extended 110kb upstream, and 40kb downstream) within each  $r^2$ -based loci definition from known and replicating novel loci were input into the pathway-based set over-representation analysis module of ConsensusPathDB (CPDB) database and tools<sup>62</sup> with 229 of 277 gene identifiers translated. In addition, these same symbols were used for Ingenuity pathway analysis (IPA; [www.ingenuity.com](http://www.ingenuity.com); a curated database of the relationships between genes obtained from published articles, and genetic and expression data repositories) to identify biological pathways common to genes. IPA determines whether the associated genes are significantly enriched in a

specific biological function or network by assessing direct interactions. We assigned significance if right-tailed Fisher's exact test p-value < 0.05. eQTL/meQTL, PCHiC and locus gene intersections were visualized using the UpSetR package (v1.3.2)<sup>63</sup>.

## Tissue overrepresentation

To assay the enrichment of variants associated with AR in tissue specific gene expression sets, we utilized the DEPICT enrichment method<sup>64</sup>, using a p-value threshold of 1e-5, and standard settings.

## Enrichment of regulatory regions

To assay the enrichment of variants associated with AR in regions of open chromatin and specific histone marks, we utilized the GWAS Analysis of Regulatory or Functional Information Enrichment with LD correction (GARFIELD v. 1) method<sup>65</sup>. In essence, GARFIELD performs greedy pruning of GWAS markers ( $LD\ r^2 > 0.1$ ) and then annotates them based on functional information overlap. Next, it quantifies Fold Enrichment (FE) at various GWAS significance cutoffs and assesses them by permutation testing, while adjusting for minor allele frequency, distance to nearest transcription start site and number of LD proxies ( $r^2 > 0.8$ ). GARFIELD was run with 10,000,000 permutations, and otherwise default settings.

## PARF

Population-attributable risk fractions (PARFs) were estimated from B58C, a general-population sample with participant ages 44-45 years also contributing to the discovery stage. The genetic risk score was calculated by applying the pooled per-allele coefficients ( $\ln(OR)$  values) from the AR discovery set to the number of higher-risk alleles of each of the 41 established (known genome-wide significant and novel replicated loci), one SNP per locus. Because there were no individuals observed with zero higher-risk alleles, the prevalence of sensitization for individuals in the lowest decile of the genetic risk score distribution was used to derive PARF estimates on the assumption that this 10% of the population was unexposed. This method has the advantage that it does not predict beyond the bounds of the data, but its results are conservative. The PARF was then derived (with 95% confidence interval) by expressing the difference between the observed prevalence and the predicted (unexposed) prevalence as a percentage of the observed prevalence. PARFs were estimated using the 41 AR loci in relation to AR, AS and NAR, respectively.

## Protein network and drug interactions

In order to analyse protein-protein-drug interaction networks, STRING (V10)<sup>66</sup> was used. Protein network data (9606.protein.links.v10.txt.gz) and protein alias data (9606.protein.aliaes.v10.txt) files were downloaded from the string db website [<http://string-db.org/>]. GWAS hits stratified on 'all', 'blood' and 'lung' were converted to Ensembl protein ids using the protein alias data. The interactors were subsequently identified using the link data at a 'high confidence cutoff of >0.7'

as described in the STRING FAQ. The interactor Ensembl protein ids were then converted to UniProt gene names and both hits and interactors were then analyzed for interactions with FDA approved drugs using the ChEMBL Database v. 22<sup>67</sup> API via Python (v. 2.7.12). Lastly, stratified networks consisting of GWAS hits connected to interactors and drugs connected to both GWAS hits and interactors were visualised using GGraph (v. 1.0.0), iGraph (v. 1.0.1), TidyVerse (v. 1.1.1) under R (v. 3.3.2).

## Data availability

Genome-wide results, excluding 23andMe, are available on request through the corresponding author. The full GWAS summary statistics for the 23andMe discovery data set will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Please contact David Hinds (dhinds@23andme.com) for more information and to apply to access the 23andMe data. A **Life Sciences Reporting Summary** is available for this paper.

## Methods section references

36. Winkler, T. W. *et al.* Quality control and conduct of genome-wide association meta-analyses. *Nat. Protoc.* **9**, 1192–1212 (2014).
37. Mägi, R. & Morris, A. P. GWAMA: software for genome-wide association meta-analysis. *BMC Bioinformatics* **11**, 288 (2010).
38. Segrè, A. V. *et al.* Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. *PLoS Genet.* **6**, (2010).
39. Karolchik, D. *et al.* The UCSC Table Browser data retrieval tool. *Nucleic Acids Res.* **32**, D493–6 (2004).
40. Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 15545–15550 (2005).
41. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. *Am. J. Hum. Genet.* **88**, 76–82 (2011).
42. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, 7 (2015).
43. UK10K Consortium *et al.* The UK10K project identifies rare variants in health and disease. *Nature* **526**, 82–90 (2015).
44. Wellcome Trust Case Control Consortium *et al.* Bayesian refinement of association signals for 14 loci in 3 common diseases. *Nat. Genet.* **44**, 1294–1301 (2012).
45. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, 122 (2016).
46. Zheng, X. *et al.* HIBAG--HLA genotype imputation with attribute bagging. *Pharmacogenomics J.* **14**, 192–200 (2014).
47. Jia, X. *et al.* Imputing amino acid polymorphisms in human leukocyte antigens. *PLoS One* **8**, e64683 (2013).



727 48. Tian, C. *et al.* Genome-wide association and HLA region fine-mapping studies identify  
728 susceptibility loci for multiple common infections. *Nat. Commun.* **8**, (2017).

729 49. Berman, H. M. The Protein Data Bank. *Nucleic Acids Res.* **28**, 235–242 (2000).

730 50. Vita, R. *et al.* The immune epitope database (IEDB) 3.0. *Nucleic Acids Res.* **43**, D405–12  
731 (2015).

732 51. Sethi, D. K., Gordo, S., Schubert, D. A. & Wucherpfennig, K. W. Crossreactivity of a human  
733 autoimmune TCR is dominated by a single TCR loop. *Nat. Commun.* **4**, 2623 (2013).

734 52. Rückert, C. *et al.* Conformational dimorphism of self-peptides and molecular mimicry in a  
735 disease-associated HLA-B27 subtype. *J. Biol. Chem.* **281**, 2306–2316 (2006).

736 53. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits.  
737 *Nat. Genet.* **47**, 1236–1241 (2015).

738 54. Zheng, J. *et al.* LD Hub: a centralized database and web interface to perform LD score  
739 regression that maximizes the potential of summary level GWAS data for SNP heritability  
740 and genetic correlation analysis. *Bioinformatics* **33**, 272–279 (2017).

741 55. Kettunen, J. *et al.* Genome-wide association study identifies multiple loci influencing human  
742 serum metabolite levels. *Nat. Genet.* **44**, 269–276 (2012).

743 56. Lucas, A. O. Surveillance of communicable diseases in tropical Africa. *Int. J. Epidemiol.* **5**,  
744 39–43 (1976).

745 57. Westra, H.-J. *et al.* Systematic identification of trans eQTLs as putative drivers of known  
746 disease associations. *Nat. Genet.* **45**, 1238–1243 (2013).

747 58. Fairfax, B. P. *et al.* Genetics of gene expression in primary immune cells identifies cell type-  
748 specific master regulators and roles of HLA alleles. *Nat. Genet.* **44**, 502–510 (2012).

749 59. Nicodemus-Johnson, J. *et al.* DNA methylation in lung cells is associated with asthma  
750 endotypes and genetic risk. *JCI Insight* **1**, e90151 (2016).

751 60. Javierre, B. M. *et al.* Lineage-Specific Genome Architecture Links Enhancers and Non-

- coding Disease Variants to Target Gene Promoters. *Cell* **167**, 1369–1384.e19 (2016).
61. Cairns, J. *et al.* CHiCAGO: robust detection of DNA looping interactions in Capture Hi-C data. *Genome Biol.* **17**, 127 (2016).
62. Kamburov, A. *et al.* ConsensusPathDB: toward a more complete picture of cell biology. *Nucleic Acids Res.* **39**, D712–7 (2011).
63. Conway, J. R., Lex, A. & Gehlenborg, N. UpSetR: An R Package For The Visualization Of Intersecting Sets And Their Properties. (2017). doi:10.1101/120600
64. Pers, T. H. *et al.* Biological interpretation of genome-wide association studies using predicted gene functions. *Nat. Commun.* **6**, 5890 (2015).
65. Iotchkova, V. *et al.* GARFIELD - GWAS Analysis of Regulatory or Functional Information Enrichment with LD correction. *bioRxiv* 085738 (2016). doi:10.1101/085738
66. Szklarczyk, D. *et al.* STRING v10: protein-protein interaction networks, integrated over the tree of life. *Nucleic Acids Res.* **43**, D447–52 (2015).
67. Bento, A. P. *et al.* The ChEMBL bioactivity database: an update. *Nucleic Acids Res.* **42**, D1083–90 (2014).

# Genome-wide association and HLA fine-mapping studies identify risk loci and genetic pathways underlying allergic rhinitis

Johannes Waage<sup>1†</sup>, Marie Standl<sup>2†</sup>, John A Curtin<sup>3</sup>, Leon E Jessen<sup>1</sup>, Jonathan Thorsen<sup>1</sup>, Chao Tian<sup>4</sup>, Nathan Schoettler<sup>5</sup>, The 23andMe\_Research\_Team<sup>6</sup>, AAGC\_collaborators<sup>6</sup>, Carlos Flores<sup>7,8</sup>, Abdel Abdellaoui<sup>9,10</sup>, Tarunveer S Ahluwalia<sup>1</sup>, Alexessander C Alves<sup>1†</sup>, Andre F S Amaral<sup>12</sup>, Josep M Antó<sup>13</sup>, Andreas Arnold<sup>14</sup>, Amalia Barreto-Luis<sup>7</sup>, Hansjörg Baurecht<sup>15</sup>, Catharina EM van Beijsterveldt<sup>9</sup>, Eugene R Bleeker<sup>16</sup>, Sílvia Bonàs-Guarch<sup>17</sup>, Dorret I Boomsma<sup>9,18</sup>, Susanne Brix<sup>19</sup>, Supinda Bunyavanich<sup>20</sup>, Esteban Burchard<sup>21,22</sup>, Zhanghua Chen<sup>23</sup>, Ivan Curjuric<sup>24,25</sup>, Adnan Custovic<sup>26</sup>, Herman T den Dekker<sup>27,28</sup>, Shyamali C Dharmage<sup>29</sup>, Julia Dmitrieva<sup>30</sup>, Liesbeth Duijts<sup>27,28,31</sup>, Markus J Ege<sup>32</sup>, W James Gauderman<sup>23</sup>, Michel Georges<sup>30</sup>, Christian Gieger<sup>33,34</sup>, Frank Gilliland<sup>23</sup>, Raquel Graneli<sup>35</sup>, Hongsheng Gui<sup>36</sup>, Torben Hansen<sup>37</sup>, Joachim Heinrich<sup>2,38</sup>, John Henderson<sup>35</sup>, Natalia Hernandez-Pacheco<sup>7,39</sup>, Patrick Holt<sup>40</sup>, Medea Imboden<sup>24,25</sup>, Vincent WV Jaddoe<sup>28,41</sup>, Marjo-Riitta Jarvelin<sup>11,42,43,44</sup>, Deborah L Jarvis<sup>12</sup>, Kamilla K Jensen<sup>45</sup>, Ingileif Jónsdóttir<sup>46,47</sup>, Michael Kabesch<sup>48</sup>, Jaakko Kaprio<sup>49,50,51</sup>, Ashish Kumar<sup>24,52,53</sup>, Young-Ae Lee<sup>54,55</sup>, Albert M Levin<sup>56</sup>, Xingnan Li<sup>57</sup>, Fabian Lorenzo-Diaz<sup>39</sup>, Erik Melén<sup>52,58</sup>, Josep M Mercader<sup>17,59,60</sup>, Deborah A Meyers<sup>16</sup>, Rachel Myers<sup>5</sup>, Dan L Nicolae<sup>5</sup>, Ellen A Nohr<sup>61</sup>, Teemu Palviainen<sup>50</sup>, Lavinia Paternoster<sup>35</sup>, Craig E Pennell<sup>62</sup>, Göran Pershagen<sup>52,63</sup>, Maria Pino-Yanes<sup>7,8,39</sup>, Nicole M Probst-Hensch<sup>24,25</sup>, Franz Rüschemann<sup>64</sup>, Angela Simpson<sup>3</sup>, Kari Stefansson<sup>46,47</sup>, Jordi Sunyer<sup>13</sup>, Gardar Sveinbjörnsson<sup>46</sup>, Elisabeth Thiering<sup>2,64</sup>, Philip J Thompson<sup>65</sup>, Maties Torrent<sup>66</sup>, David Torrents<sup>17,67</sup>, Joyce Y Tung<sup>4</sup>, Carol A Wang<sup>68</sup>, Stephan Weidinger<sup>15</sup>, Scott Weiss<sup>69</sup>, Gonneke Willemsen<sup>9</sup>, L Keoki Williams<sup>36,70</sup>, Carole Ober<sup>5</sup>, David A Hinds<sup>4</sup>, Manuel A. Ferreira<sup>71</sup>, Hans Bisgaard<sup>1</sup>, David P Strachan<sup>72</sup>, Klaus Bønnelykke<sup>1</sup>

<sup>1</sup>COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. <sup>2</sup>Institute of Epidemiology I, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany. <sup>3</sup>Division of Infection, Immunity and Respiratory Medicine, The University of Manchester, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK. <sup>4</sup>23andMe, Inc., Mountain View, California, USA. <sup>5</sup>Department of Human Genetics, University of Chicago, Chicago IL, USA. <sup>6</sup>Listed in the Supplementary Information. <sup>7</sup>Research Unit, Hospital Universitario N.S. de Candelaria, Universidad de La Laguna, Tenerife, Spain. <sup>8</sup>CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. <sup>9</sup>Department of Biological Psychology, Netherlands Twin Register, VU University, Amsterdam, The Netherlands. <sup>10</sup>Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. <sup>11</sup>Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment & Health, School of Public Health, Imperial College, London, UK. <sup>12</sup>Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College London, London, UK. <sup>13</sup>ISGlobal-Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra (UPF), CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain. <sup>14</sup>Clinic and Polyclinic of Dermatology, University Medicine Greifswald, Greifswald, Germany. <sup>15</sup>Department of Dermatology, Venereology and Allergology, University-Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. <sup>16</sup>Divisions of Pharmacogenomics and Genetics, Genomics and Precision Medicine, Department of Medicine, University of Arizona College of Medicine, Tucson, AZ, USA. <sup>17</sup>Barcelona Supercomputing Center (BSC). Joint BSC-CRG-IRB Research Program in Computational Biology, Barcelona, Spain. <sup>18</sup>EMGO Institute for Health and Care Research, Amsterdam, The Netherlands. <sup>19</sup>Department of Biotechnology and Biomedicine, Technical University of Denmark, Kgs. Lyngby, Denmark. <sup>20</sup>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. <sup>21</sup>Department of Medicine, University of California San Francisco, San Francisco, California, USA. <sup>22</sup>Department of Bioengineering & Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA. <sup>23</sup>Dept of Preventive Medicine, University of Southern California, Keck School of Medicine. <sup>24</sup>University of Basel, Basel, Switzerland. <sup>25</sup>Swiss Tropical and Public Health Institute, Basel, Switzerland. <sup>26</sup>Department of Paediatrics, Imperial College, London, UK. <sup>27</sup>The Generation R Study Group, Department of Pediatrics, division of Respiratory Medicine, Rotterdam, the Netherlands. <sup>28</sup>Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands. <sup>29</sup>Allergy and Lung Health Unit, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia. <sup>30</sup>Laboratory of Animal Genomics, Unit of Medical Genomics, GIGA Institute, University of Liège, Belgium. <sup>31</sup>Department of Pediatrics, division of Neonatology, Rotterdam, the Netherlands. <sup>32</sup>LMU Munich, Dr von Hauner Children's Hospital, Munich and German Center for Lung Research (DZL), Munich, Germany. <sup>33</sup>Research Unit of Molecular Epidemiology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany. <sup>34</sup>Institute of Epidemiology II, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany. <sup>35</sup>MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, UK. <sup>36</sup>Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, MI, USA. <sup>37</sup>Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Department of

Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. <sup>38</sup>Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University of Munich Medical Center, Ludwig-Maximilians-Universität München, Munich, Germany. <sup>39</sup>Genomics and Health Group, Department of Biochemistry, Microbiology, Cell Biology and Genetics, Universidad de La Laguna, La Laguna, Tenerife, Spain. <sup>40</sup>Telethon Kids Institute (TKI), Perth, Australia. <sup>41</sup>The Generation R Study Group, Department of Pediatrics, Rotterdam, the Netherlands. <sup>42</sup>Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland. <sup>43</sup>Biocenter Oulu, University of Oulu, Oulu, Finland. <sup>44</sup>Unit of Primary Care, Oulu University Hospital, Oulu, Finland. <sup>45</sup>Department of Bio and Health Informatics, Technical University of Denmark, Kgs. Lyngby, Denmark. <sup>46</sup>deCODE genetics / Amgen Inc, Reykjavik, Iceland. <sup>47</sup>Faculty of Medicine, University of Iceland, Reykjavik, Iceland. <sup>48</sup>Department of Pediatric Pneumology and Allergy, University Children's Hospital Regensburg (KUNO), Regensburg, Germany. <sup>49</sup>Department of Public Health, University of Helsinki, Helsinki, Finland. <sup>50</sup>Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland. <sup>51</sup>National Institute for Health and Welfare, Helsinki, Finland. <sup>52</sup>Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. <sup>53</sup>Department of Public Health Epidemiology, Unit of Chronic Disease Epidemiology, Swiss Tropical and Public Health Institute, Basel, Switzerland. <sup>54</sup>Max-Delbrück-Center (MDC) for Molecular Medicine, Berlin, Germany. <sup>55</sup>Clinic for Pediatric Allergy, Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin, Germany. <sup>56</sup>Department of Public Health Sciences, Henry Ford Health System, Detroit, MI, USA. <sup>57</sup>Divisions of Genetics, Genomics and Precision Medicine, Department of Medicine, University of Arizona College of Medicine, Tucson, AZ, USA. <sup>58</sup>Sachs' Children's Hospital, Stockholm, Sweden. <sup>59</sup>Programs in Metabolism and Medical & Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. <sup>60</sup>Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. <sup>61</sup>Institute of Clinical Research, University of Southern Denmark, Department of Obstetrics & Gynecology, Odense University Hospital, Odense, Denmark. <sup>62</sup>School of Medicine and Public Health, Faculty of Medicine and Health, The University of Newcastle, Callaghan, Australia. <sup>63</sup>Centre for Occupational and Environmental Medicine, Stockholm County Council, Stockholm. <sup>64</sup>Ludwig-Maximilians-University of Munich, Dr. von Hauner Children's Hospital, Division of Metabolic Diseases and Nutritional Medicine, Munich, Germany. <sup>65</sup>Institute for Respiratory Health, Harry Perkins Institute of Medical Research, University of Western Australia, Nedlands, Australia. <sup>66</sup>Ib-Salut, Area de Salut de Menorca, Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma de Mallorca, Spain. <sup>67</sup>Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. <sup>68</sup>Division of Obstetrics and Gynaecology, School of Medicine, The University of Western Australia (UWA), Perth, Australia. <sup>69</sup>Channing Division of Network Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, USA. <sup>70</sup>Department of Internal Medicine, Henry Ford Health System, Detroit, MI, USA. <sup>71</sup>QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. <sup>72</sup>Population Health Research Institute, St George's, University of London, London, UK.

†These authors contributed equally to this work

#### Corresponding author

Klaus Bønnelykke, MD, PhD

COPSAC, Copenhagen Prospective Studies on Asthma in Childhood  
Herlev and Gentofte Hospital  
Ledreborg Allé 34  
2820 Gentofte  
Denmark  
Email: kb@copsac.com

## Introduction

Allergic rhinitis is the most common clinical presentation of allergy, affecting 400 million people worldwide, and with increasing incidence in westernized countries.<sup>1,2</sup> To elucidate the genetic architecture and understand disease mechanisms of allergic rhinitis, we carried out a meta-analysis of allergic rhinitis in 59,762 cases and 152,358 controls of European ancestry and identified a total of 41 risk loci for allergic rhinitis, including 20 loci not previously associated with allergic rhinitis, which were confirmed in a replication phase of 60,720 cases and 618,527 controls. Functional annotation implied genes involved in various immune pathways, and fine mapping of the HLA region suggested amino acid variants of importance for antigen binding. We further performed GWASs of allergic sensitization against inhalant allergens and non-allergic rhinitis suggesting shared genetic mechanisms across rhinitis-related traits. Future studies of the identified loci and genes might identify novel targets for treatment and prevention of allergic rhinitis.

## Main text

Allergic rhinitis (AR) is an inflammatory disorder of the nasal mucosa mediated by allergic hypersensitivity responses to environmental allergens<sup>1</sup> with large adverse effects on quality of life and health care expenditures. The underlying causes for AR are still not understood and prevention of the disease is not possible. The heritability of AR is estimated to be more than 65%<sup>3,4</sup>. Seven loci have been associated with allergic rhinitis in genome-wide association studies (GWAS) of AR per se, while other have been suggested from GWAS studies on related traits, such as self-reported allergy, asthma plus hay fever, or allergic sensitization<sup>5-9</sup>, but only few of these have been replicated.

We carried out a large-scale meta-GWAS of AR including a discovery meta-analysis of 16,531,985 genetic markers from 18 studies comprising 59,762 cases and 152,358 controls of primarily European ancestry (**Supplementary Table 1**, cohort recruitment details in **Supplementary Note**). We report the genetic heritability on the liability scale of AR as at least 7.8% (assuming 10% disease prevalence), with a genomic inflation of 1.048 (**Supplementary Figure 1**). We identified 42 genetic loci, with index markers below genomewide significance ( $p < 5e-8$ ), of which 21 have previously been reported in relation to AR or other inhalant allergy<sup>6-9</sup> (**Fig. 1, Table 1, Table 2, Supplementary Fig. 2, Supplementary Fig. 3**).

One study (23andMe) had a proportionally large weight (~80%) in the discovery phase. Overall there was good agreement between 23andMe and the other studies with respect to effect size and direction, and regional association patterns (**Supplementary Table 2 and Supplementary Fig. 4+5**), and the genetic correlation was 0.80 ( $p < 2e-17$ ). Heterogeneity between 23andMe and the remaining studies was statistically significant ( $p < 0.05$ ) for 7 of 42 loci, in most cases due to a smaller effect size in 23andMe. This was likely due to many non-23andMe studies using a more robust phenotype definition of doctor diagnosed AR (**Supplementary Table 3**), which tended to result in larger effect sizes (**Supplementary Table 4**).

The index markers from a total of 25 loci that had not previously been associated with AR or other inhalant allergy were carried forward to the replication phase. These included 16 loci that showed genome-wide significant association in the discovery phase and evidence of association ( $p < 0.05$ ) in both 23andMe and non-23andMe studies (**Supplementary Table 2**), and an additional 9 loci that were selected from the p-value stratum between  $5 \times 10^{-8}$  and  $1 \times 10^{-6}$  based on enrichment of gene sets involved in immune-signaling (**Supplementary Table 5**). Replication was sought in another 10 studies with 60,720 cases and 618,527 controls. Of the 25 loci, 20 loci reached a Bonferroni-corrected significance threshold of 0.05 ( $p < 0.0019$ ) in a meta-analysis of replication studies (**Fig. 1 (blue), Table 2**), and all of these reached genome-wide significance in the combined fixed-effect meta-analysis of discovery and replication studies (**Table 2**). Evidence of heterogeneity was seen for one of these loci (rs1504215), which did not reach statistical significance in the random effects model (0.95 [0.92; 0.97],  $p = 2.83 \times 10^{-7}$ , **Supplementary Fig. 3**).

A conditional analysis of top loci identified 13 additional independent variants at  $p < 1 \times 10^{-5}$ , with 4 of these being genome-wide significant (near *WDR36*, *HLA-DQB1*, *IL1RL1* and *LPP*) (**Supplementary Table 6** and **Supplementary Fig. 5**, bottom panel).

To gain insight into functional consequences of known and novel loci, we utilized a number of data sources, including 1) 11 eQTL sets and 1 meQTL set from blood and blood subsets; 2) 2 eQTL sets and 1 meQTL set from lung tissue; and 3) data on enhancer-promoter interactions in 15 different blood subsets. Support of regulatory effects on coding genes was found for 33 out of the 41 loci. Many loci showed evidence of regulatory effects across a wide range of immune cell types (including B- and T-cells), while other seemed cell type-specific (**Supplementary Table 7**). Calculation of the “credible set” of markers for each locus using a Bayesian approach that selects markers likely to contain the causal disease-associated markers (**Supplementary Table 8**) and looking up these in the Variant Effect Predictor database generated a list of 17 markers producing amino acid changes, including deleterious changes in NUSAP1, SULT1A1 and PLCL, as predicted by SIFT (**Supplementary Table 9**).

The major histocompatibility complex (MHC) on chr6p harbored some of the strongest association signals in the GWAS with independent signals located around *HLA-DQB* and *HLA-B*, respectively. The top variant at *HLA-DQB* was an eQTL for several HLA-genes, including *HLA-DQB1*, *HLA-DQA1*, *HLA-DQA2*, and *HLA-DRB1* in immune and/or lung tissue, and the top variant at *HLA-B* was an eQTL for *MICA* (**Supplementary Table 7**). In addition we found associations with several classical HLA alleles, including HLA-DQB1\*02:02, HLA-DQB1\*03:01, HLA-DRB1\*04:01, and HLA-C\*04:01, which were in weak LD ( $r^2 < 0.1$ ) with the GWAS top SNPs (**Supplementary Tables 10 and 11**), and strong associations with well imputed amino acid variants, including HLA-DQB1 His30 ( $p = 2.06 \times 10^{-28}$ , OR=0.91) and HLA-B AspHisLeu116 ( $p = 6.00 \times 10^{-13}$ , OR=1.06) (**Supplementary Tables 12 and 13**). Within HLA-DQB1, the amino acid variant was in moderate LD ( $r^2 = 0.71$ ) with the GWAS top SNP and accounted for most of the SNP association (rs34004019,  $p = 2.18 \times 10^{-28}$ , OR=0.88, conditional p-value= $1.35 \times 10^{-3}$ ). Within HLA-B, the strongest associated amino acid variant was only in weak LD ( $r^2 = 0.23$ ) with the top SNP and accounted for a small part of the SNP association (rs2428494,  $p = 3.99 \times 10^{-15}$ , OR=1.07, conditional p-value= $3.23 \times 10^{-10}$ ). Importantly, the strongest associated amino acid variants in HLA-DQB1 and HLA-B, respectively were both located in the peptide binding pockets with a

high likelihood of affecting MHC-peptide interaction (**Figure 2**). MHC class II molecules, including HLA-DQ, are known for their role in allergen-binding and Th2 driven immune responses<sup>10</sup> and our results therefore suggest that the GWAS signal at this locus involves structural changes related to allergen binding properties. This might be in addition to gene regulatory effects similar to what has been found for autoimmune disease.<sup>11,12</sup>

The majority of the 20 loci not previously associated with AR per se imply genes with a known role in the immune system, including IL7R<sup>13, 14</sup>, SH2B3<sup>15</sup>, CEBPA/CEBPG<sup>16, 17</sup>, CXCR5<sup>18</sup>, FCER1G, NFKB1<sup>19</sup>, BACH2<sup>20, 21</sup>, TYRO3<sup>22</sup>, LTK<sup>23</sup>, VPRBP<sup>24</sup>, SPPL3<sup>25</sup>, OASL<sup>26</sup>, RORA<sup>27</sup>, and TNFSF11<sup>28</sup>. Other loci imply genes with no clear function in AR pathogenesis. These include one of the strongest associated loci in this meta-analysis at 12q24.31 with the top-signal located between CDK2AP1 and C12orf65, harboring cis-eQTLs in blood and lung tissue for several genes and evidence for enhancer-promoter interaction with DDX55 in various immune cells. (**Supplementary Table 14** and further locus description in the **Supplementary Note**).

Concomitantly with the current study, a GWAS combining asthma, eczema and AR was conducted.<sup>29</sup> The majority (15/20) of identified AR loci in our study were also suggested in the previous, more unspecific, GWAS<sup>29</sup> (as indicated in Table 2), while many suggested loci from the previous GWAS were not identified in our study. Asthma, eczema and allergic rhinitis are related but distinct disease entities, often with separate disease mechanisms, e.g. allergic sensitization is present in only 50% of children with asthma<sup>30</sup> and 35% of children with eczema.<sup>31</sup> Our results therefore complement those from the less specific “atopic phenotype” GWAS<sup>29</sup> by pinpointing loci specifically associated, and replicated, in relation to allergic rhinitis.

AR loci were significantly enriched ( $p < 1e-5$ ) for variants reported to be associated with autoimmune disorders. Reported autoimmune variants were located within a 1mb distance of 31 (76%) of the 41 AR loci. For 24 of these, an autoimmune top SNP was also associated with AR, and for 12 of these the autoimmune top SNP was in LD ( $r^2 > 0.5$ ) with the AR top SNP (**Supplementary Table 15**). For approximately half of these, the direction of effect was the same for the autoimmune and AR top SNP in line with a previous study,<sup>32</sup> underlining the complex genetic relationship between AR and autoimmunity, which might involve shared as well as diverging molecular mechanisms.

Assessment of enrichment of AR-associated variant burden in open chromatin as defined by DNase hypersensitive sites showed a clear enrichment in several blood and immune cell subsets, with the largest enrichment in T-cells (CD3 expressing), B-cells (CD19 expressing), and T and NK-cells (CD56-expressing) (**Fig. 3, Supplementary Table 16, Supplementary Fig. 6**). We also probed tissue enrichment by means of gene expression data from a wide number of sources, showing enrichment of AR genes in blood and immune cell subsets, as well as in tissues of the respiratory system, including oropharynx, respiratory and nasal mucosa (**Supplementary Table 17**).

To explore biological connections and identify new pathways associated with AR, we combined all genes suggested from eQTL/meQTL analyses, enhancer-promoter interactions and localization within the top loci. The resultant prioritized gene set consisted of 255 genes, of which 89 (~36%) were present in more than one set (**Supplementary Fig. 7**). Overall, the full set was enriched for pathways involved in Th1 and Th2 Activation (**Fig. 4**), antigen presentation, cytokine signaling, and inflammatory responses (**Supplementary Table 18**).

Using the 255 prioritized genes in combination with STRING to identify proteins that interact with the proteins encoded by the high priority genes, we demonstrated a high degree of interaction at the protein level, and several of these proteins are target of approved drugs or drugs in development, including TNFSF11, NDUFAF1, PD-L1, IL-5, and IL-13 (**Fig. 4**).

AR is strongly correlated to allergic sensitization (presence of allergen-specific IgE), but sensitization is often present without AR suggesting specific mechanisms determining progression from sensitization to disease. We therefore conducted a GWAS on sensitization to inhalant allergens (AS) comprising 8,040 cases and 16,441 controls from 13 studies (**Supplementary Table 1**), making it the largest GWAS on allergic sensitization to date<sup>7</sup>. A total of 10 loci reached genome-wide significance, including one novel hit near the *FASLG* gene (**Supplementary Table 19**). The genetic heritability on the liability scale was 17.75% (10% prevalence), considerably higher than the heritability of AR in consistency with a more homogeneous phenotype. Look-up of AR top-loci in the AS GWAS demonstrated large agreement with 40 of the 41 AR markers showing same direction of effect and 28 also showing nominal significance for AS (**Supplementary Table 20**). This suggests that AR and AS share biological mechanisms and that AS loci generally affect systemic allergic sensitization. We compared genetic pathways of AR and AS using the DEPICT tool showing overlap in enriched pathways but also differences among the top gene sets, with AR gene sets characterized by B-cell, Th2, and parasite responses and AS gene sets characterized by a broader activation of cells (**Supplementary Fig 8 and Supplementary Tables 21 and 22**).

Non-allergic rhinitis, defined as rhinitis symptoms without evidence of allergic sensitization, is a common but poorly understood disease entity.<sup>33</sup> We performed the first GWAS on this phenotype hypothesizing that this might reveal specific rhinitis mechanisms. The analysis included 2,028 cases and 9,606 controls from 9 studies but did not identify any risk loci at the genome-wide significance level. Comparison with AR results suggested some overlap in susceptibility loci (**Supplementary Note and Supplementary Table 23**).

We estimated the proportion of AR in the general population that can be attributed to the 41 identified AR loci and obtained a conservative population-attributable risk fraction estimate of 39% (95% CI 26%-50%), considering the 10% of the population with the lowest genetic risk scores to represent an 'unexposed' group. Allergic rhinitis prevalence plotted by genetic risk score (**Supplementary Fig. 9**) showed approximately 2 times higher prevalence in the 7% of the population with the highest risk score compared to the 7% with the lowest risk score.

Finally, we investigated the genetic correlation of AR with AS, asthma<sup>34</sup>, and eczema<sup>35</sup> by LD score regression. There was a strong correlation between AR and AS ( $r^2=0.73$ ,  $p<2e-34$ ), moderate with asthma ( $r^2=0.60$ ,  $p<3e-14$ ) and weaker with eczema ( $r^2=0.40$ ,  $p<2e-07$ ).

The identified AR loci were tested for association with AR in non-European cohorts, only showing nominal significant association for a loci, but this analysis had limited statistical power due to population sizes (**Supplementary Table 24**).

In conclusion, we expanded the number of established susceptibility loci for AR and highlighted involvement of AR susceptibility loci in diverse immune cell types and both innate and adaptive IgE-related mechanisms. Future studies of novel AR loci might identify targets for treatment and prevention of disease.



276

## 277 Acknowledgments

278 Detailed acknowledgments and funding details are provided for each contributing study in the  
279 **Supplementary Note**.

280

## 281 Author contributions

282 Study design and management: K.B., J.W., M.S., D.P.S. Meta-analyses: M.S., J.W. Manuscript  
283 writing: K.B., J.W., M.S., J.A.C., J.T., L.E.J. M.A.F. Systems biology analyses: J.W., J.A.C., J.T.,  
284 L.E.J., J.M.M., S.B.-G., D.T. Data collection, analysis and design in the individual contributing  
285 studies: K.B., J.W., M.S., J.A.C., C.F., A. Abdellaoui, T.S.A., A. Alves, A.F.S.A., J.M.A, A.  
286 Arnold, A.B.-L., H. Baurecht, C.E.M.B., E.R.B, D.I.B., S. Bunyavanich, E.B., Z.C., I.C., A.C.,  
287 H.T.D., S.C.D., J.D., L.D., M.J.E., W.J.G., C.G., F.G., R.G., H.G., T.H., J. Heinrich, J.  
288 Henderson, N. H.-P., D.A.H., P.H., M.I., V.W.V.J., M.-R.J., D.L.J., I.J., M.K., J.K., A.K., Y.-A.L.,  
289 A.M.L., X.L., F.L.-D., E.M., D.A.M., R.M., D.L.N., E.A.N., T.P., L.P., C.E.P., G.P., M.P.-Y.,  
290 N.M.P.-H., F.R., A.S., K.S., J.S., G.S., E.T., P.J.T., C.T., M.T., J.Y.T., C.A.W., S.Weidinger,  
291 S.Weiss, G.W., L.K.W., C.O., M.A.F., H. Bisgaard, D.P.S. Immunological interpretation: N.S.,  
292 S.Brix. Gene expression analysis: M.G., J.D. Protein modeling: K.K.J.

293

## 294 Competing financial interests

295 G.S., I.J., and K.S. are affiliated with deCODE genetics/Amgen declare competing financial  
296 interests as employees. C.T., D.A.H., J.Y.T., and the 23andMe Research Team are employees  
297 of and hold stock and/or stock options in 23andMe, Inc. L.P. has received a fee for participating  
298 in a scientific input engagement meeting from Merck Sharp & Dohme Limited, outside of the  
299 submitted work.

300

## 301 References

- 302 1. Greiner, A. N., Hellings, P. W., Rotiroti, G. & Scadding, G. K. Allergic rhinitis. *Lancet* **378**,  
303 2112–2122 (2011).
- 304 2. Björkstén, B. *et al.* Worldwide time trends for symptoms of rhinitis and conjunctivitis: Phase  
305 III of the International Study of Asthma and Allergies in Childhood. *Pediatr. Allergy*  
306 *Immunol.* **19**, 110–124 (2008).

- 307 3. Willemsen, G., van Beijsterveldt, T. C. E. M., van Baal, C. G. C. M., Postma, D. &  
308 Boomsma, D. I. Heritability of self-reported asthma and allergy: a study in adult Dutch  
309 twins, siblings and parents. *Twin Res. Hum. Genet.* **11**, 132–142 (2008).
- 310 4. Fagnani, C. *et al.* Heritability and shared genetic effects of asthma and hay fever: an Italian  
311 study of young twins. *Twin Res. Hum. Genet.* **11**, 121–131 (2008).
- 312 5. Ramasamy, A. *et al.* A genome-wide meta-analysis of genetic variants associated with  
313 allergic rhinitis and grass sensitization and their interaction with birth order. *J. Allergy Clin.*  
314 *Immunol.* **128**, 996–1005 (2011).
- 315 6. Hinds, D. A. *et al.* A genome-wide association meta-analysis of self-reported allergy  
316 identifies shared and allergy-specific susceptibility loci. *Nat. Genet.* **45**, 907–911 (2013).
- 317 7. Bønnelykke, K. *et al.* Meta-analysis of genome-wide association studies identifies ten loci  
318 influencing allergic sensitization. *Nat. Genet.* **45**, 902–906 (2013).
- 319 8. Ferreira, M. A. R. *et al.* Genome-wide association analysis identifies 11 risk variants  
320 associated with the asthma with hay fever phenotype. *J. Allergy Clin. Immunol.* **133**, 1564–  
321 1571 (2014).
- 322 9. Bunyavanich, S. *et al.* Integrated genome-wide association, coexpression network, and  
323 expression single nucleotide polymorphism analysis identifies novel pathway in allergic  
324 rhinitis. *BMC Med. Genomics* **7**, 48 (2014).
- 325 10. Jahn-Schmid, B., Pickl, W. F. & Bohle, B. Interaction of Allergens, Major Histocompatibility  
326 Complex Molecules, and T Cell Receptors: A ‘Ménage à Trois’ That Opens New Avenues  
327 for Therapeutic Intervention in Type I Allergy. *Int. Arch. Allergy Immunol.* **156**, 27–42  
328 (2011).
- 329 11. Cavalli, G. *et al.* MHC class II super-enhancer increases surface expression of HLA-DR  
330 and HLA-DQ and affects cytokine production in autoimmune vitiligo. *Proc. Natl. Acad. Sci.*  
331 *U. S. A.* **113**, 1363–1368 (2016).

12. Hayashi, M. *et al.* Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A\*02:01 in vivo. *Proc. Natl. Acad. Sci. U. S. A.* **113**, 1357–1362 (2016).
13. Puel, A., Ziegler, S. F., Buckley, R. H. & Leonard, W. J. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. *Nat. Genet.* **20**, 394–397 (1998).
14. Lundmark, F. *et al.* Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. *Nat. Genet.* **39**, 1108–1113 (2007).
15. Mori, T. *et al.* Lnk/Sh2b3 controls the production and function of dendritic cells and regulates the induction of IFN- $\gamma$ -producing T cells. *J. Immunol.* **193**, 1728–1736 (2014).
16. Scott, L. M., Civin, C. I., Rorth, P. & Friedman, A. D. A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. *Blood* **80**, 1725–1735 (1992).
17. Gao, H., Parkin, S., Johnson, P. F. & Schwartz, R. C. C/EBP gamma has a stimulatory role on the IL-6 and IL-8 promoters. *J. Biol. Chem.* **277**, 38827–38837 (2002).
18. León, B. *et al.* Regulation of T(H)2 development by CXCR5+ dendritic cells and lymphotoxin-expressing B cells. *Nat. Immunol.* **13**, 681–690 (2012).
19. Lawrence, T. The nuclear factor NF-kappaB pathway in inflammation. *Cold Spring Harb. Perspect. Biol.* **1**, a001651 (2009).
20. Shinnakasu, R. *et al.* Regulated selection of germinal-center cells into the memory B cell compartment. *Nat. Immunol.* **17**, 861–869 (2016).
21. Roychoudhuri, R. *et al.* BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers. *Nat. Immunol.* **17**, 851–860 (2016).
22. Rothlin, C. V., Ghosh, S., Zuniga, E. I., Oldstone, M. B. A. & Lemke, G. TAM receptors are pleiotropic inhibitors of the innate immune response. *Cell* **131**, 1124–1136 (2007).
23. Chan, P. Y. *et al.* The TAM family receptor tyrosine kinase TYRO3 is a negative regulator

of type 2 immunity. *Science* **352**, 99–103 (2016).

24. Kassmeier, M. D. *et al.* VprBP binds full-length RAG1 and is required for B-cell development and V(D)J recombination fidelity. *EMBO J.* **31**, 945–958 (2012).
25. Hamblet, C. E., Makowski, S. L., Tritapoe, J. M. & Pomerantz, J. L. NK Cell Maturation and Cytotoxicity Are Controlled by the Intramembrane Aspartyl Protease SPPL3. *J. Immunol.* **196**, 2614–2626 (2016).
26. Andersen, J. B., Strandbygård, D. J., Hartmann, R. & Justesen, J. Interaction between the 2'-5' oligoadenylate synthetase-like protein p59 OASL and the transcriptional repressor methyl CpG-binding protein 1. *Eur. J. Biochem.* **271**, 628–636 (2004).
27. Halim, T. Y. F. *et al.* Retinoic-acid-receptor-related orphan nuclear receptor alpha is required for natural helper cell development and allergic inflammation. *Immunity* **37**, 463–474 (2012).
28. Anderson, D. M. *et al.* A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. *Nature* **390**, 175–179 (1997).
29. Ferreira, M. A. *et al.* Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. *Nat. Genet.* **49**, 1752–1757 (2017).
30. Pearce, N., Pekkanen, J. & Beasley, R. How much asthma is really attributable to atopy? *Thorax* **54**, 268–272 (1999).
31. Bohme, M., Wickman, M., Lennart Nordvall, S., Svartengren, M. & Wahlgren, C. F. Family history and risk of atopic dermatitis in children up to 4 years. *Clin. Exp. Allergy* **33**, 1226–1231 (2003).
32. Kreiner, E. *et al.* Shared genetic variants suggest common pathways in allergy and autoimmune diseases. *J. Allergy Clin. Immunol.* (2017). doi:10.1016/j.jaci.2016.10.055
33. Bousquet, J. *et al.* Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. *Allergy* **63**, 842–853 (2008).

34. Moffatt, M. F. *et al.* Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. *Nature* **448**, 470–473 (2007).
35. Paternoster, L. *et al.* Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. *Nat. Genet.* **47**, 1449–1456 (2015).

390

## 391 Figure legends

### 392 **Figure 1: Manhattan plot of the meta-GWAS discovery phase**

393 Circular plot of p-values from a inverse variance weighted fixed-effect meta-analysis of  
394 association of 16,531,985 genetic markers to allergic rhinitis from the discovery phase, including  
395 212,120 individuals. Only markers with  $p < 1e-3$  are shown. Labels indicate nearest gene name  
396 for index marker in locus (marker with lowest p-value). Green labels indicate loci previously  
397 associated with allergy; blue labels indicate novel AR loci; grey labels indicate novel loci that  
398 were not carried forward to the replication phase. Green line indicates level of genome wide  
399 significance ( $p = 5e-8$ ).

400

### 401 **Figure 2: Structural visualization of amino acid variants associated with allergic rhinitis**

402 The surface of the MHC molecule is shown in white, while the backbone of the bound peptide is  
403 shown in dark gray. The amino acid variant in focus is highlighted in red and the peptide binding  
404 pockets of the MHC molecule is indicated with dashed circles and annotated P1-P9. (A) The  
405 amino acid variant with strongest association to AR is HLA-DQB1 His30 (MHC class II), located  
406 close to P6 with a distance of 6Å to the peptide (excluding the peptide side chain). The  
407 protective amino acid variant at this location in relation to AR is histidine, whereas the risk  
408 variant is serine. Histidine is positively charged and has a large aromatic ring, whereas serine is  
409 not charged and not aromatic. Therefore, this mutation results in a significant change of the  
410 binding pocket environment. (B) The strongest AR-associated amino acid variation in HLA-B  
411 (MHC class I) is HLA-B AspHisLeu116, located close to P9 with a distance of 7Å to the peptide  
412 (excluding the peptide side chain). The close proximity to the bound peptide for both variants  
413 indicates that they are likely to affect the MHC-peptide interaction and thereby which peptides  
414 are presented.

415

### 416 **Figure 3: Enrichment of allergic rhinitis-associated variants in tissue-specific open 417 chromatin**

418 Enrichment of 16,531,985 genetic variants associated with allergic rhinitis in 212,120 individuals  
419 (at  $p < 1e-08$  as threshold for marker association) in 189 cell types from ENCODE and  
420 Roadmap epigenomics data. Enrichment and p-value was calculated empirically against a  
421 permuted genomic background using the GARFIELD tool. Red labels indicate blood and blood-  
422 related cell-types, grey labels indicate other cell types. Due to number of permutations =  $1e7$ ,  
423 empirical p-values reached a minimum ceiling of  $1/1e7$ . FDR threshold = 0.00026. For Epstein-  
424 Barr virus transformed B-lymphocyte cell types (cell type "GM\*\*\*\*"), only most enriched instance  
425 is shown ("B-Lymphocyte"). NHEK = normal human epidermal keratinocytes, HMEC/vHMEC =  
426 mammary epithelial cells, HCM = human cardiac myocytes, WI-38 = lung fibroblast-derived,

427 HRGEC = human renal glomerular endothelial cell, HCFaa = Human Cardiac Fibroblasts-Adult  
428 Atrial cell, HMVEC-dBI-Neo = human microvascular endothelial cells, Th1 = T helper cell, type  
429 1, Th2 = T helper cell, type 2.

430  
431 **Figure 4: Interaction network between drugs and proteins from genes associated with**  
432 **allergic rhinitis**  
433 Grey nodes represent locus genes as well as genes prioritized from e/meQTL and PCHiC  
434 sources, based on genetics association of 16,531,985 markers with allergic rhinitis in 212,120  
435 individuals. Blue nodes represent drugs from the ChEMBL drug database. Edges represent  
436 very-high confidence interactions from the STRING database (for locus-locus interactions) and  
437 drug target evidence (for drug-locus interactions). Red borders indicate genes with protein  
438 products that were significantly enriched in the “Th1 and Th2 Activation” pathway (-log[p-value]  
439 >19.1) from the IPA pathway analysis.  
440

**Table 1.** Association results of index markers (variant with lowest p-value for each locus) previously reported in relation to AR or other inhalant allergy. Column “Nearest gene” denotes nearest up- and downstream gene (for intergenic variants with two genes listed), or surrounding gene (for intronic variants with one gene listed), with the exception of rs5743618, an exonic missense variant within *TLR1*. EA/OA=effect allele/other allele. P-value is calculated from the logistic regression model. Het.P=p-value for heterogeneity obtained from Cochrane’s Q test.

Variant	Locus	Nearest genes	EA/OA	Discovery					
				EAF	n (studies)	OR	95% conf.int	P	Het. P
Known									
rs34004019	6p21.32	HLA-DQB1;HLA-DQA1	G/A	0.27	196,951 (11)	0.89	0.87-0.90	1.00E-30	0.41
rs950881	2q12.1	IL1RL1;IL1RL1	T/G	0.15	212,120 (18)	0.88	0.87-0.90	1.74E-30	0.91
rs5743618	4p14	TLR1;TLR10	A/C	0.27	210,652 (17)	0.90	0.89-0.92	4.38E-27	0.70
rs1438673	5q22.1	CAMK4;WDR36	C/T	0.50	212,120 (18)	1.08	1.07-1.10	3.15E-26	0.26
rs7936323	11q13.5	LRR32;C11orf30	A/G	0.48	212,120 (18)	1.08	1.06-1.09	6.53E-24	0.0001
rs2428494	6p21.33	HLA-B;HLA-C	A/T	0.42	195,753 (12)	1.08	1.06-1.09	7.01E-19	0.25
rs11644510	16p13.13	RMI2;CLEC16A	T/C	0.37	212,120 (18)	0.93	0.92-0.95	1.58E-17	0.65
rs12939457	17q12	GSDMB;ZPBP2	C/T	0.44	212,120 (18)	0.94	0.92-0.95	2.35E-17	0.02
rs148505069	4q27	IL21;IL2	G/A	0.33	212,120 (18)	1.07	1.05-1.08	2.54E-15	0.02
rs13395467	2p25.1	ID2;RNF144A	G/A	0.28	212,120 (18)	0.94	0.92-0.95	9.93E-15	0.61
rs9775039	9p24.1	IL33;RANBP6	A/G	0.16	212,120 (18)	1.08	1.06-1.10	2.22E-14	0.40
rs2164068	2q33.1	PLCL1	A/T	0.49	212,120 (18)	0.94	0.93-0.96	4.21E-14	0.82
rs2030519	3q28	TPRG1;LPP	G/A	0.49	212,120 (18)	1.06	1.04-1.07	1.83E-13	0.12
rs11256017	10p14	CELF2;GATA3	T/C	0.18	212,120 (18)	1.07	1.05-1.09	2.72E-12	0.60
rs17294280	15q22.33	AAGAB;SMAD3	G/A	0.25	212,120 (18)	1.07	1.05-1.09	5.97E-12	0.07
rs7824993	8q21.13	ZBTB10;TPD52	A/G	0.37	212,120 (18)	1.05	1.04-1.07	1.86E-10	0.56
rs9282864	16p11.2	SULT1A1;SULT1A2	C/A	0.33	208,761 (16)	0.94	0.93-0.96	4.69E-10	0.03
rs9687749	5q31.1	IL13;RAD50	T/G	0.44	207,604 (16)	1.06	1.04-1.09	1.84E-09	0.19
rs61977073	14q21.1	TTC6	G/A	0.22	212,120 (18)	1.06	1.04-1.08	5.78E-09	0.05
rs6470578	8q24.21	TMEM75;MYC	T/A	0.28	212,120 (18)	1.05	1.03-1.07	4.36E-08	0.02
rs3787184	20q13.2	NFATC2;KCNG1	G/A	0.19	207,604 (16)	0.94	0.93-0.96	4.76E-08	0.69



**Table 2.** Association results of index markers (variant with lowest p-value for each locus) not previously associated with AR reaching a Bonferroni-corrected significance threshold of 0.05 in the replication phase. Column “Nearest gene” denotes nearest up- and downstream gene (for intergenic variants with two genes listed), or surrounding gene (for intronic variants with one gene listed), with the exception of rs1504215, an exonic synonymous variant within *BACH2*. EA/OA=effect allele/other allele. P-value is calculated from the logistic regression model. Het.P=p-value for heterogeneity obtained from Cochrane’s Q test. \* Variants also reported associated with a combined asthma/eczema/hay fever phenotype by Ferreira et al.<sup>29</sup> (within +/- 1Mb).

Variant	Locus	Nearest genes	EA/OA	Discovery						Replication						Combined			
				EA	n (studies)	OR	95% conf.int	P	Het. P	n (studies)	OR	95% conf.int	P	FWER	n (studies)	OR	95% conf.int	P	Het. P
rs7717955*	5p13.2	CAPSL; IL7R	T/C	0.27	212,120 (18)	0.95	0.93-0.96	1.50E-09	0.24	679,247 (10)	0.93	0.91-0.94	4.09E-25	1.06E-23	891,367 (28)	0.94	0.93-0.95	3.78E-32	0.09
rs63406760*	12q24.31	CDK2AP1; C12orf65	G/-	0.26	210,652 (17)	0.93	0.91-0.95	5.12E-14	0.91	675,338 (7)	0.95	0.93-0.96	3.27E-12	8.51E-11	885,990 (24)	0.94	0.93-0.95	2.54E-24	0.89
rs1504215*	6q15	BACH2; GJA10	A/G	0.34	207,604 (16)	0.95	0.94-0.97	1.49E-08	0.02	679,247 (10)	0.95	0.94-0.97	1.99E-11	5.17E-10	886,851 (26)	0.95	0.94-0.96	1.54E-18	0.05
rs28361986*	11q23.3	CXCR5; DDX6	A/T	0.20	212,120 (18)	0.93	0.91-0.95	1.81E-14	0.87	675,919 (8)	0.94	0.93-0.96	7.92E-11	2.06E-09	888,039 (26)	0.94	0.92-0.95	2.32E-23	0.91
rs2070902*	1q23.3	ALS90714.1; FCER1G	T/C	0.25	212,120 (18)	1.06	1.04-1.08	1.03E-10	0.18	679,247 (10)	1.05	1.03-1.06	7.27E-10	1.89E-08	891,367 (28)	1.05	1.04-1.06	6.19E-19	0.23
rs111371454*	15q15.1	ITPKA; RTF1	G/A	0.21	212,120 (18)	1.06	1.03-1.08	1.65E-07	0.17	675,338 (7)	1.04	1.03-1.06	8.47E-09	2.20E-07	887,458 (25)	1.05	1.03-1.06	1.28E-14	0.22
rs12509403*	4q24	MANBA; NFKB1	T/C	0.32	212,120 (18)	0.95	0.94-0.97	9.97E-09	0.27	679,247 (10)	0.96	0.95-0.97	1.86E-08	4.84E-07	891,367 (28)	0.96	0.95-0.97	1.17E-15	0.39
rs9648346*	7p15.1	JAZF1; TAX1BP1	G/C	0.22	207,604 (16)	1.05	1.03-1.07	3.62E-08	0.74	679,247 (10)	1.04	1.03-1.06	1.39E-07	3.63E-06	886,851 (26)	1.05	1.03-1.06	3.30E-14	0.48
rs35350651*	12q24.12	ATXN2; SH2B3	C/-	0.49	206,136 (15)	1.04	1.03-1.06	6.63E-08	0.60	672,701 (6)	1.04	1.02-1.05	1.41E-07	3.66E-06	878,837 (21)	1.04	1.03-1.05	5.82E-14	0.43
rs2519093*	9q34.2	ABO; OBP2B	T/C	0.20	212,120 (18)	1.06	1.04-1.09	4.96E-11	0.38	675,919 (8)	1.04	1.03-1.06	2.96E-07	7.68E-06	888,039 (26)	1.05	1.04-1.07	2.79E-16	0.61
rs62257549	3p21.2	VPRBP	A/G	0.20	212,120 (18)	0.95	0.93-0.97	7.13E-08	0.45	677,615 (9)	0.96	0.94-0.97	3.37E-07	8.76E-06	889,735 (27)	0.95	0.94-0.97	1.84E-13	0.53
rs11677002	2p23.2	FOSL2; RBKS	C/T	0.45	212,120 (18)	0.96	0.95-0.98	3.80E-07	0.21	679,247 (10)	0.97	0.96-0.98	3.54E-07	9.20E-06	891,367 (28)	0.97	0.96-0.97	7.08E-13	0.36
rs35597970*	10q24.32	ACTR1A; TMEM180	-/A	0.45	210,652 (17)	1.06	1.04-1.07	1.34E-13	0.96	676,970 (8)	1.03	1.02-1.05	4.37E-07	1.14E-05	887,622 (25)	1.04	1.03-1.05	5.42E-18	0.53
rs2815765	1p31.1	LRRIQ3; NEGR1	T/C	0.37	212,120 (18)	0.95	0.94-0.97	1.18E-09	0.59	679,247 (10)	0.97	0.95-0.98	6.16E-07	1.60E-05	891,367 (28)	0.96	0.95-0.97	9.45E-15	0.52
rs11671925*	19q13.11	CEBPA; SLC7A10	A/G	0.17	206,136 (15)	0.94	0.92-0.96	1.80E-08	0.97	677,551 (9)	0.96	0.94-0.98	2.80E-06	7.29E-05	883,687 (24)	0.95	0.94-0.96	5.91E-13	0.60
rs2461475*	12q24.31	SPPL3; ACADS	C/T	0.47	212,120 (18)	1.04	1.02-1.05	9.19E-07	0.97	677,551 (9)	1.03	1.02-1.04	6.52E-06	0.0002	889,671 (27)	1.03	1.02-1.04	3.81E-11	0.83
rs6738964*	2q36.3	SPHKAP; DAW1	G/T	0.24	212,120 (18)	0.96	0.94-0.97	4.51E-07	0.72	679,247 (10)	0.97	0.96-0.98	4.96E-05	0.0013	891,367 (28)	0.96	0.95-0.97	1.86E-10	0.87
rs10519067*	15q22.2	RORA	A/-	0.13	212,120 (18)	0.93	0.91-0.96	1.78E-09	0.37	442,354 (7)	0.93	0.90-0.96	7.53E-05	0.0020	654,474 (25)	0.93	0.92-0.95	5.53E-13	0.36
rs138050288*	1p36.23	RERE; SLC45A1	-/CA	0.29	210,652 (17)	1.05	1.04-1.07	5.96E-10	0.71	675,338 (7)	1.03	1.01-1.04	0.0002	0.0046	885,990 (24)	1.04	1.03-1.05	6.62E-12	0.63
rs7328203	13q14.11	TNFSF11; AKAP11	G/T	0.46	212,120 (18)	1.05	1.03-1.06	5.94E-09	0.90	677,551 (9)	1.02	1.01-1.04	0.0005	0.0134	889,671 (27)	1.03	1.02-1.04	1.28E-10	0.78

## Methods:

### Phenotype definition

#### Allergic rhinitis (AR)

Cases were defined as individuals ever having a diagnosis or symptoms of AR dependent on available phenotype definitions in the included studies (**Supplementary Table 3** and cohort recruitment details in **Supplementary Note**). All relevant ethical regulations were followed as specified in relation to the individual studies in the **Supplementary Note**. To maximize numbers and optimize statistical power, we did not require doctor-diagnosed AR or verification by allergic sensitization. This approach was confirmed by a sensitivity analysis in 23andMe based on association with known risk loci for allergic rhinitis (data not shown). Controls were defined as individuals who never had a diagnosis or symptoms of AR.

#### Allergic sensitization (AS)

We considered specific IgE production against inhalant allergens without restriction by assessment method or type of inhalant allergen. Cases were defined as individuals with objectively measured sensitization against at least one of the inhalant allergens tested for in the respective studies, and controls were defined as individuals who were not sensitized against any of the allergens tested for. We included sensitization assessed by skin reaction after puncture of the skin with a droplet of allergen extract (SPT) and/or by detection of the levels of circulating allergen-specific IgE in the blood. The SPT wheal diameter cutoffs were 3 mm larger than the negative control for cases and smaller than 1 mm for controls. To optimize case specificity and the correlation between methods, we chose a high cutoff of specific IgE levels for cases (0.7 IU/ml) and a low cutoff for controls (0.35 IU/ml).

#### Non-allergic rhinitis (NAR)

Cases were defined as individuals with current allergic rhinitis symptoms (within the last 12 months) and no allergic sensitization (negative specific IgE ( $< 0.35$  IU/mL) and/or negative skin prick test ( $< 1$  mm) for all allergens and time points tested)

Controls were defined as individuals never having symptoms of allergic rhinitis and no allergic sensitization (negative specific IgE ( $< 0.35$  IU/mL) and/or negative skin prick test ( $< 1$  mm) for all allergens and time points tested)

For all 3 phenotypes, we combined data from children and adults but chose a lower age limit of 6 years, as allergic rhinitis and sensitization status at younger ages show poorer correlation with status later in life, both owing to transient symptoms/sensitization status and frequent development of symptoms/sensitization during late childhood.

### GWAS QC and cohort summary data harmonization

For AR, AS, and NAR, each cohort imputed their data separately using the 1000 Genomes Project (1KGP) phase 1, version 3 release, and conducted the genome-wide association

analysis adjusted for sex and if necessary for age and principal components (**Supplementary Table 3**). All studies included individuals of European descent, except Generation R and RAINE, comprising a mixed, multi-ethnic population. We utilized EasyQC v. 9.2<sup>36</sup> for quality control and marker harmonization for cohort-level meta-GWAS summary files. Cohort data was harmonized to genome build GRCh37 and checked against 1KGP phase 3 reference allele frequencies for processing problems. GWAS summary “karyograms” were visually inspected to catch cohorts with incomplete data. Distributions of estimate coefficients and errors, as well as “Standard error vs. sample size”- and “p value vs. z-score” plots were inspected for each cohort for systematic errors in statistical models. Ambiguous markers that were non-unique in terms of both genomic position and allele coding were removed. A minimum imputation score of 0.3 ( $R^2$ ) or 0.4 (proper\_info) was required for markers. A minimum minor allele count of 7 was required for each marker in each cohort, as suggested by the GIANT consortium and EasyQC.

## Meta-Analysis

For AR, AS, and NAR, meta-analysis for the discovery phase was conducted using GWAMA<sup>37</sup> with an inverse variance weighted fixed-effect model with genomic control correction of the individual studies. Each locus is represented by the variant showing the strongest evidence within a 1Mb buffer. Loci were inspected visually by plotting genomic neighbourhood and coloring for 1KGP  $r^2$  values. From the pool of genomewide significant markers in the discovery, one locus with index marker rs193243426 without a credible LD structure was removed from further analysis (**Supplementary Fig. 10**). Heterogeneity was assessed with Cochran’s Q test. Meta-analysis of replication candidates from the AR discovery phase was carried out using R version 3.4.0, and the *meta* package version 4.8-2 with an inverse variance weighted fixed-effect model. For a subset of markers, cohorts reported suitable proxies ( $r^2 > 0.85$ ), where followed-up markers were not present or had insufficient imputation or genotyping quality (**Supplementary Table 25**).

## Gene set overrepresentation analysis, discovery phase

To facilitate selection of biologically relevant discovery candidates in the sub-genomewide significant stratum ( $5e-8 < p < 1e-6$ ), we employed a custom gene set overrepresentation analysis algorithm implemented in R, with a scoring and permutation regime modeled after MAGENTA.<sup>38</sup> Genes with lengths less than 200bp, with copies on multiple chromosomes, and with multiple copies on the same chromosome more than 1Mb apart were removed from analysis. Gene models (GENCODE v 19) were downloaded from the UCSC Table Browser,<sup>39</sup> and expanded 110 kb upstream, and 40 kb downstream, similar to MAGENTA. The HLA region was excluded from analysis (chromosome 6: 29,691,116-33,054,976). Similar to MAGENTA, gene scores were adjusted for number of markers per gene, gene width, recombination hotspots, genetic distance, and number of independent markers per gene, all with updated data from UCSC Table Browser. For the gene set overrepresentation permutation calculation, gene sets from the MSigDB collections c2, c3, c5, c7, and hallmark, were included.<sup>40</sup> A MAGENTA-style enrichment cutoff at 95% was used. Gene sets with  $FDR < 0.05$  were considered.

## Conditional analyses

To identify additional independent markers at each discovery genomic region, we used Genome-wide Complex Trait Analysis (GCTA) v. 1.26.0.<sup>41</sup> Within a window of +/- 1Mb of each discovery phase index marker, all markers were conditioned on the index using the --cojo-cond feature of GCTA with default parameters. Plink v. 1.90b3.42<sup>42</sup> was used to calculate  $r^2$  for GCTA with the UK10K full genotype panel<sup>43</sup> as reference. A total of 42 of 52 markers from the full discovery phase were present in UK10K. As a MAF-dependent inflation of conditional p-values was observed (data not shown), only conditional markers with MAF  $\geq 10\%$  were selected.

## Locus definition and credible sets for VEP annotation

Discovery loci were defined as index markers extended with markers in LD ( $r^2 \geq 0.5$ ), based on the 1KGP phase 3. Protein coding gene transcript models (GENCODE v. 24) were downloaded from the UCSC Table Browser, and nearest upstream, downstream, as well as all genes within the extended loci were annotated.

Credible sets for each locus were calculated using the method of Morris, A.P.<sup>44</sup>.

LD was calculated for each discovery index variant within +/- 500 kb, and markers with  $r^2 < 0.1$  were excluded. For the remaining markers, the Bayesian Factor (ABF) values and the posterior probabilities (PostProb) were calculated, and cumulative posterior probability values were generated based ranking markers on ABF. Finally, variants were included in the 99% credible set until the cumulative posterior probability was greater or equal than 0.99.

Credible sets for each loci was annotated with information on mutation impact in coding regions using the Variant effect Prediction (VeP) REST API<sup>45</sup>, exporting only the nonsynonymous substitutions.

## GWAS catalogue lookup

For annotation of markers with identification in previous GWA studies, the GWAS catalog was downloaded from NHGRI-EBI (v.1.0.1, 2016-11-28). For this analysis, AR loci were lifted from genomic build GRCh37 to GRCh38, and extended with +/- 1Mb in each direction before being overlapped with GWAS catalog annotations. Relevant GWAS catalog overlap traits were binned into trait groups "Allergic Rhinitis", "Asthma", "Autoimmune", "Eczema", "Infectious Diseases", "Lung-related Traits", and "Other allergy". A million random genomic intervals of the same length (2Mb) were obtained to generate a background overlap distribution, and p-values were calculated from this background.

## HLA classical allele analysis

Analyses of imputed classical HLA-alleles were performed in the 23andMe study (AR discovery population) comprising 49,180 individuals with allergic rhinitis and 124,102 controls.

HLA imputation was performed with HIBAG.<sup>46</sup> We imputed allelic dosage for HLA-A, B, C, DPB1, DQA1, QB1, and DRB1 loci at four-digit resolution using the default settings of HIBAG for a total of 292 classical HLA alleles.

Using an approach suggested by P. de Bakker,<sup>47</sup> we downloaded the files that map HLA alleles to amino acid sequences from <https://www.broadinstitute.org/mpg/snp2hla/> and mapped our imputed HLA alleles at four-digit resolution to the corresponding amino acid sequences; in this way we translated the imputed HLA allelic dosages directly to amino acid dosages. We encoded all amino acid variants in the 23andMe European samples as 2395 bi-allelic amino acid polymorphisms as previously described.<sup>48</sup>

Similar to the SNP imputation, we measured imputation quality using  $r^2$ , which is the ratio of the empirically observed variance of the allele dosage to the expected variance assuming Hardy-Weinberg equilibrium.

To test associations between imputed HLA alleles, amino acid variants, and phenotypes, we performed logistic regression using the same set of covariates used in the SNP-based GWAS. We applied a forward stepwise strategy, within each type of variant, to establish statistically independent signals in the HLA region. Within each variant type, we first identified the most strongly associated signals (lowest p-value) and performed forward iterative conditional regression to identify other independent signals. All analyses were controlled for sex and five principal components of genetic ancestry. The p-values were calculated using a likelihood ratio test.

## Structural visualization of amino acid variants

Structural visualization of amino acid variants was performed for the strongest associated variants in HLA-DQB1 (position 30) and HLA-B (position 116), respectively (**Supplementary Table 10**) and were made using X-ray structures from the Protein Data Bank (PDB).<sup>49</sup> To find the best structure we used the specialized search function in the Immune Epitope Database,<sup>50</sup> selecting only X-ray crystalized structures for the specific MHC classes HLA-DQB1 (class II) and HLA-B (class I). Using this criterion, we found 17 crystallized structures for HLA-DQB1 and 164 structures for HLA-B. From these lists, we selected the structure with the lowest resolution and the amino acids encoded by the reported top SNPs. The PDB accession code for the selected structures was 4MAY<sup>51</sup> for HLA-DQB1 and 2A83<sup>52</sup> for HLA-B and both structures were visualized using PyMOL v. 1.8.2.1 (<http://www.pymol.org>). Furthermore, we used PyMOL to measure intra-molecular distances from the side chain of the amino acids associated with allergic rhinitis to the C $\alpha$  atoms in the peptide. This distance measure was chosen to accommodate the possibility for different amino acids in the peptide. In order for two amino acids to interact the distance should be approximately 4Å or less. We measured distances of 6Å (HLA-DQB1) and 7Å (HLA-B). However these distances do not include the peptide side chains which range from 1.5 Å – 8.8 Å. Therefore, we estimate that physical interaction between the amino acids encoded by the top SNPs and the peptide is likely.

## Genetic heritability and genetic correlation

For calculating genetic heritability and genetic correlation between AR and AS, as well as between clinical cohorts and 23andMe within AR, we utilized the LD score regression based method as implemented by LDSC v. 1.0.<sup>45,53</sup> Population prevalence was set to 10% for AR and

AS. Genetic correlation analysis between AR, AS and published GWAS studies was carried out using the LDHUB platform v. 1.3.1<sup>54</sup> against all traits, but excluding Metabolites<sup>55</sup>.

## eQTL sources and analysis

From GTEx V6p<sup>56</sup>, all significant variant-gene cis eQTL pairs for whole blood, lung, and EBV-transformed lymphocytes were downloaded from <https://gtexportal.org>, and carried forward in analysis. From Westra et al.<sup>57</sup>, both cis and trans eQTLs in whole blood were downloaded, and variant-gene pairs with FDR < 0.1 were carried forward in analysis. From Fairfax et al.<sup>58</sup>, cis eQTLs from monocytes and B cells were downloaded, and variant-gene pairs with FDR < 0.1 were carried forward in analyses. From Bonder et al.<sup>58</sup>, meQTLs from whole blood were downloaded, and variant-probe pairs with FDR < 0.05 were carried forward in analyses. From Nicodemus-Johnson et al.<sup>59</sup>, cis eQTLs and meQTLs from lung were downloaded, and variant-gene pairs with FDR < 0.1 were carried forward in analyses. From Momozawa et al. [in press, personal correspondence], cis eQTLs from blood cell types CD14, CD15, CD19, CD4, and CD8 were downloaded, and variant-gene pairs with a weighted correlation of  $\geq 0.6$  were carried forward to analysis. For supplementary table 14 priority genes, protein coding information was downloaded from the UCSC Table Browser, using the “transcriptClass” field from the “wgEncodeGencodeAttrsV24lift37” table.

## Promoter Capture Hi-C Gene Prioritisation

To assess spatial promoter interactions in the discovery set, we performed a Capture Hi-C Gene Prioritisation (CHIGP) as described in Javierre et al.<sup>60</sup> and <https://github.com/ollyburren/CHIGP> using recommended settings and data sources: 0.1cM recombination blocks, 1KGP EUR reference population, coding markers from the GRCh37 Ensembl assembly and the CHICAGO-generated<sup>61</sup> Promoter Capture Hi-C peak matrix data from 17 human primary blood cell types supplied in the original paper. The resulting protein-coding prioritized genes (gene score > 0.5) were used in the downstream network analysis, from cell types "Fetal thymus", "Total CD4 T cells", "Activated total CD4 T cells", "Non-activated total CD4 T cells", "Naive CD4 T cells", "Total CD8 T cells", "Naive CD8 T cells", "Total B cells", "Naive B cells", "Endothelial precursors", "Macrophages M0", "Macrophages M1", "Macrophages M2", "Monocytes", and "Neutrophils".

## Gene set overrepresentation analysis of known and replicating novel loci

All high-confidence gene symbols from eQTL and meQTL sources, PCHiC, as well as genes (models extended 110kb upstream, and 40kb downstream) within each  $r^2$ -based loci definition from known and replicating novel loci were input into the pathway-based set over-representation analysis module of ConsensusPathDB (CPDB) database and tools<sup>62</sup> with 229 of 277 gene identifiers translated. In addition, these same symbols were used for Ingenuity pathway analysis (IPA; [www.ingenuity.com](http://www.ingenuity.com); a curated database of the relationships between genes obtained from published articles, and genetic and expression data repositories) to identify biological pathways common to genes. IPA determines whether the associated genes are significantly enriched in a

specific biological function or network by assessing direct interactions. We assigned significance if right-tailed Fisher's exact test p-value < 0.05. eQTL/meQTL, PCHiC and locus gene intersections were visualized using the UpSetR package (v1.3.2)<sup>63</sup>.

## Tissue overrepresentation

To assay the enrichment of variants associated with AR in tissue specific gene expression sets, we utilized the DEPICT enrichment method<sup>64</sup>, using a p-value threshold of 1e-5, and standard settings.

## Enrichment of regulatory regions

To assay the enrichment of variants associated with AR in regions of open chromatin and specific histone marks, we utilized the GWAS Analysis of Regulatory or Functional Information Enrichment with LD correction (GARFIELD v. 1) method<sup>65</sup>. In essence, GARFIELD performs greedy pruning of GWAS markers ( $LD\ r^2 > 0.1$ ) and then annotates them based on functional information overlap. Next, it quantifies Fold Enrichment (FE) at various GWAS significance cutoffs and assesses them by permutation testing, while adjusting for minor allele frequency, distance to nearest transcription start site and number of LD proxies ( $r^2 > 0.8$ ). GARFIELD was run with 10,000,000 permutations, and otherwise default settings.

## PARF

Population-attributable risk fractions (PARFs) were estimated from B58C, a general-population sample with participant ages 44-45 years also contributing to the discovery stage. The genetic risk score was calculated by applying the pooled per-allele coefficients ( $\ln(OR)$  values) from the AR discovery set to the number of higher-risk alleles of each of the 41 established (known genome-wide significant and novel replicated loci), one SNP per locus. Because there were no individuals observed with zero higher-risk alleles, the prevalence of sensitization for individuals in the lowest decile of the genetic risk score distribution was used to derive PARF estimates on the assumption that this 10% of the population was unexposed. This method has the advantage that it does not predict beyond the bounds of the data, but its results are conservative. The PARF was then derived (with 95% confidence interval) by expressing the difference between the observed prevalence and the predicted (unexposed) prevalence as a percentage of the observed prevalence. PARFs were estimated using the 41 AR loci in relation to AR, AS and NAR, respectively.

## Protein network and drug interactions

In order to analyse protein-protein-drug interaction networks, STRING (V10)<sup>66</sup> was used. Protein network data (9606.protein.links.v10.txt.gz) and protein alias data (9606.protein.aliaes.v10.txt) files were downloaded from the string db website [<http://string-db.org/>]. GWAS hits stratified on 'all', 'blood' and 'lung' were converted to Ensembl protein ids using the protein alias data. The interactors were subsequently identified using the link data at a 'high confidence cutoff of >0.7'

as described in the STRING FAQ. The interactor Ensembl protein ids were then converted to UniProt gene names and both hits and interactors were then analyzed for interactions with FDA approved drugs using the ChEMBL Database v. 22<sup>67</sup> API via Python (v. 2.7.12). Lastly, stratified networks consisting of GWAS hits connected to interactors and drugs connected to both GWAS hits and interactors were visualised using GGraph (v. 1.0.0), iGraph (v. 1.0.1), TidyVerse (v. 1.1.1) under R (v. 3.3.2).

## Data availability

Genome-wide results, excluding 23andMe, are available on request through the corresponding author. The full GWAS summary statistics for the 23andMe discovery data set will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Please contact David Hinds (dhinds@23andme.com) for more information and to apply to access the 23andMe data. A **Life Sciences Reporting Summary** is available for this paper.



## Methods section references

36. Winkler, T. W. *et al.* Quality control and conduct of genome-wide association meta-analyses. *Nat. Protoc.* **9**, 1192–1212 (2014).
37. Mägi, R. & Morris, A. P. GWAMA: software for genome-wide association meta-analysis. *BMC Bioinformatics* **11**, 288 (2010).
38. Segrè, A. V. *et al.* Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. *PLoS Genet.* **6**, (2010).
39. Karolchik, D. *et al.* The UCSC Table Browser data retrieval tool. *Nucleic Acids Res.* **32**, D493–6 (2004).
40. Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 15545–15550 (2005).
41. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. *Am. J. Hum. Genet.* **88**, 76–82 (2011).
42. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, 7 (2015).
43. UK10K Consortium *et al.* The UK10K project identifies rare variants in health and disease. *Nature* **526**, 82–90 (2015).
44. Wellcome Trust Case Control Consortium *et al.* Bayesian refinement of association signals for 14 loci in 3 common diseases. *Nat. Genet.* **44**, 1294–1301 (2012).
45. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, 122 (2016).
46. Zheng, X. *et al.* HIBAG--HLA genotype imputation with attribute bagging. *Pharmacogenomics J.* **14**, 192–200 (2014).
47. Jia, X. *et al.* Imputing amino acid polymorphisms in human leukocyte antigens. *PLoS One*

730       **8**, e64683 (2013).

731   48. Tian, C. *et al.* Genome-wide association and HLA region fine-mapping studies identify  
732       susceptibility loci for multiple common infections. *Nat. Commun.* **8**, (2017).

733   49. Berman, H. M. The Protein Data Bank. *Nucleic Acids Res.* **28**, 235–242 (2000).

734   50. Vita, R. *et al.* The immune epitope database (IEDB) 3.0. *Nucleic Acids Res.* **43**, D405–12  
735       (2015).

736   51. Sethi, D. K., Gordo, S., Schubert, D. A. & Wucherpfennig, K. W. Crossreactivity of a human  
737       autoimmune TCR is dominated by a single TCR loop. *Nat. Commun.* **4**, 2623 (2013).

738   52. Rückert, C. *et al.* Conformational dimorphism of self-peptides and molecular mimicry in a  
739       disease-associated HLA-B27 subtype. *J. Biol. Chem.* **281**, 2306–2316 (2006).

740   53. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits.  
741       *Nat. Genet.* **47**, 1236–1241 (2015).

742   54. Zheng, J. *et al.* LD Hub: a centralized database and web interface to perform LD score  
743       regression that maximizes the potential of summary level GWAS data for SNP heritability  
744       and genetic correlation analysis. *Bioinformatics* **33**, 272–279 (2017).

745   55. Kettunen, J. *et al.* Genome-wide association study identifies multiple loci influencing human  
746       serum metabolite levels. *Nat. Genet.* **44**, 269–276 (2012).


747   56. Lucas, A. O. Surveillance of communicable diseases in tropical Africa. *Int. J. Epidemiol.* **5**,  
748       39–43 (1976).



749   57. Westra, H.-J. *et al.* Systematic identification of trans eQTLs as putative drivers of known  
750       disease associations. *Nat. Genet.* **45**, 1238–1243 (2013).

751   58. Fairfax, B. P. *et al.* Genetics of gene expression in primary immune cells identifies cell type-  
752       specific master regulators and roles of HLA alleles. *Nat. Genet.* **44**, 502–510 (2012).

753   59. Nicodemus-Johnson, J. *et al.* DNA methylation in lung cells is associated with asthma  
754       endotypes and genetic risk. *JCI Insight* **1**, e90151 (2016).

60. Javierre, B. M. *et al.* Lineage-Specific Genome Architecture Links Enhancers and Non-coding Disease Variants to Target Gene Promoters. *Cell* **167**, 1369–1384.e19 (2016).
61. Cairns, J. *et al.* CHiCAGO: robust detection of DNA looping interactions in Capture Hi-C data. *Genome Biol.* **17**, 127 (2016).
62. Kamburov, A. *et al.* ConsensusPathDB: toward a more complete picture of cell biology. *Nucleic Acids Res.* **39**, D712–7 (2011).
63. Conway, J. R., Lex, A. & Gehlenborg, N. UpSetR: An R Package For The Visualization Of Intersecting Sets And Their Properties. (2017). doi:10.1101/120600
64. Pers, T. H. *et al.* Biological interpretation of genome-wide association studies using predicted gene functions. *Nat. Commun.* **6**, 5890 (2015).
65. Iotchkova, V. *et al.* GARFIELD - GWAS Analysis of Regulatory or Functional Information Enrichment with LD correction. *bioRxiv* 085738 (2016). doi:10.1101/085738
66. Szklarczyk, D. *et al.* STRING v10: protein-protein interaction networks, integrated over the tree of life. *Nucleic Acids Res.* **43**, D447–52 (2015).
67. Bento, A. P. *et al.* The ChEMBL bioactivity database: an update. *Nucleic Acids Res.* **42**, D1083–90 (2014).





$-\log_{10}[\text{Empirical } p\text{-value}]$

